<SEC-DOCUMENT>0001193125-14-268510.txt : 20140715
<SEC-HEADER>0001193125-14-268510.hdr.sgml : 20140715
<ACCEPTANCE-DATETIME>20140715083857
ACCESSION NUMBER:		0001193125-14-268510
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20140715
DATE AS OF CHANGE:		20140715

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-193100
		FILM NUMBER:		14974720

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d759111d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS SUPPLEMENT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5) </B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(To Prospectus dated January&nbsp;8, 2014)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Registration No. 333-193100 </B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g759111suppcov_pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>11,299,435 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 9,604,520 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering up to 11,299,435 shares of our common stock and warrants to purchase up to 9,604,520 shares of our common stock in this offering. The common
stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.85 shares of common stock at an exercise price of $2.17 per share of common stock. Each unit will be sold at a negotiated
price of $1.77 per unit. The shares of common stock and warrants will be issued separately but can only be purchased together in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
warrant will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share. The warrants are non-transferable and will expire thirteen months from the date of issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Capital Market (NASDAQ) under the symbol &#147;STEM.&#148; On July&nbsp;14, 2014, the last reported sales price of
our common stock on NASDAQ was $2.02 per share. We do not intend to list the warrants on any securities exchange or other quotation system. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. Before buying any securities, you should read the discussion of material risks of investing in our common stock under the heading &#147;<A HREF="#supptoc759111_4">Risk factors</A>&#148; beginning on page S-5 of this
prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ascendiant Capital Markets, LLC is acting as placement agent in connection with the arrangement of this transaction, as described in &#147;Plan of
Distribution&#148; below. We have agreed to pay the placement agent the fees set forth in the table below, which assumes that we sell all of the units we are offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Unit&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Placement fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.1062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.6638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Offering price and proceeds excludes potential proceeds from the exercise of the warrants offered hereby. We have agreed to pay Ascendiant Capital Markets, LLC, the placement agent for this offering, additional
placement fees up to to 6.0% of the gross cash proceeds received by us from the exercise of any warrant offered hereby. We have also agreed to reimburse the placement agent for its reasonable out of pocket expenses, including the reasonable fees and
expenses of its counsel, in an amount not to exceed $30,000. We estimate the total expenses of this offering, excluding placement fees, will be approximately $100,000. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delivery of the shares and the warrants will be made on or before July&nbsp;18, 2014. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is July&nbsp;14, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:80.15pt; font-size:8pt; font-family:Times New Roman"><B>Prospectus Supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_1">Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_2">About this Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_3">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_6">Price Range of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_9">Description of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_10">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_12">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_13">Incorporation of Certain Documents by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_14">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_15">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_16">Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_17">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_18">Ratio of Earnings to Fixed Charges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_19">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_20">Description of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_21">Description of Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_22">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_23">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_24">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_25">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_26">Where you Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc759111_27">Incorporation of Certain Documents by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_1"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the documents incorporated in this prospectus supplement contain forward looking statements that
involve substantial risks and uncertainties. These forward-looking statements generally can be identified by the use of words such as &#147;anticipate,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;could,&#148; &#147;may,&#148; &#147;will,&#148;
&#147;believe,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;goal,&#148; &#147;project,&#148; and other words of similar meaning. Such statements include, without limitation, all statements as to expectation or belief and statements as to
our future results of operations; the progress of our research, product development and clinical programs; the need for, and timing of, additional capital and capital expenditures; partnering prospects; costs of manufacture of products; the
protection of, and the need for, additional intellectual property rights; effects of regulations; the need for additional facilities; potential market opportunities; our anticipated use of proceeds from this offering; and our ability to consummate
the offering. Our actual results may vary materially from those contained in such forward-looking statements because of risks to which we are subject, including the fact that additional trials will be required to confirm the safety and demonstrate
the efficacy of our HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether the U.S. Food and Drug Administration (FDA), Swissmedic, Health Canada or other regulatory authorities will permit us to proceed with clinical
testing of proposed products despite the novel and unproven nature of our technologies; the risk that our clinical trials or studies could be substantially delayed beyond their expected dates or cause us to incur substantial unanticipated costs;
uncertainties in our ability to obtain the capital resources needed to continue our current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; the
uncertainty regarding our ability to obtain a corporate partner or partners, if needed, to support the development and commercialization of our potential cell-based therapeutics product; the uncertainty regarding the outcome of our clinical trials
or studies we may conduct in the future; the uncertainty regarding the validity and enforceability of our issued patents; the risk that we may not be able to manufacture additional master and working cell banks when needed; the uncertainty whether
any products that may be generated in our cell-based therapeutics programs will prove clinically safe and effective; the uncertainty of whether we will achieve significant revenue from product sales or become profitable; obsolescence of our
technologies; competition from third parties; intellectual property rights of third parties; litigation risks; and other risks to which we are subject. All forward-looking statements attributable to us or to persons acting on our behalf are
expressly qualified in their entirety by the cautionary statements and risk factors set forth under the heading &#147;Risk Factors&#148; in this prospectus supplement, including the risk factors incorporated by reference from our most recent Annual
Report on Form 10-K, as updated by our other filings with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act filed after such annual report or in additional prospectus supplements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_2"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The
second part, the accompanying prospectus, gives more general information, some of which may not apply to this offering. Generally, when we refer only to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement
may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement.
This prospectus supplement, the accompanying prospectus and the documents incorporated into each by reference include important information about us, the shares being offered and other information you should know before investing in our common
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on this prospectus supplement, the accompanying prospectus and the information incorporated or deemed to be
incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectuses we have prepared. We have not, and the placement agent has not, authorized anyone to provide you with information that is in
addition to, or different from, that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectuses we have prepared. If anyone provides you with different or inconsistent
information, you should not rely on it. We are not, and the placement agent is not, offering to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained or incorporated by
reference in this prospectus supplement or the accompanying prospectus is accurate as of any date other than as of the date of this prospectus supplement or the accompanying prospectus, as the case may be, or in the case of the documents
incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any sale of our common shares. Our business, financial condition, liquidity, results of
operations, and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this prospectus to &#147;StemCells,&#148; the
&#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; mean StemCells, Inc., including our directly and indirectly wholly-owned subsidiaries, unless we state otherwise or the context otherwise requires. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of selected information contained elsewhere or incorporated by reference in this prospectus. It does not contain
all of the information that you should consider before buying our securities. You should read this entire prospectus carefully, especially the sections entitled &#147;Risk Factors,&#148; &#147;Note Regarding Forward-Looking Statements&#148; and the
consolidated financial statements and the notes to the consolidated financial statements incorporated by reference herein. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are engaged in researching, developing, and commercializing cell-based therapeutics and enabling tools and technologies for stem cell-based
research and drug discovery and development. Our research and development (R&amp;D) programs are primarily focused on identifying and developing potential cell-based therapeutics which can either restore or support organ function. In particular,
since we relocated our operations to California in 1999, our R&amp;D efforts have been directed at refining our methods for identifying, isolating, culturing, and purifying the human neural stem cell and developing this cell as potential cell-based
therapeutics for the central nervous system (CNS). Our HuCNS-SC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> cells (purified human neural stem cells) are currently in clinical development for several indications &#151; chronic spinal
cord injury, dry age-related macular degeneration (AMD) and Pelizeaus-Merzbacher disease (PMD), which is a myelination disorder in the brain. We are also conducting preclinical research to evaluate HuCNS-SC cells in Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2012, we published in <I>Science Translational Medicine</I>, a peer-reviewed journal, the data from our four-patient Phase I
clinical trial in PMD, which showed preliminary evidence of durable and progressive donor-derived myelination in all four patients. In addition, there were measurable gains in neurological function in three of the four patients, with the fourth
patient clinically stable. In April 2014, we announced the completion of enrollment in our Phase I/II clinical trial for the treatment of chronic spinal cord injury. This trial is being conducted in Switzerland, Canada, and the United States and
it&nbsp;represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury. Data from the first three patients demonstrated a favorable safety profile and multi-segment gains in sensory
function in two of the three patients 12 months after transplantation of HuCNS-SC cells compared to pre-transplant baselines; the third patient remained stable. In May 2014, we announced additional interim data from this study including the fact
that three more patients in the study, all classified as being an AIS B (or incomplete) spinal cord injury patient according to the American Spinal Injury Association Impairment Scale, had significant gains in sensory perception and the third
remained stable. The interim results also continue to confirm the favorable safety profile of the cells and the surgical implant procedure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also conducting a Phase I/II clinical trial in dry AMD at three trial sites in the United States and completed enrollment in June 2014.
This study is divided into two sequential cohorts. Subjects are enrolled into each cohort based on best-corrected visual acuity (BCVA), as determined by the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) acuity test. Patients with
BCVA of less than or equal to 20/400 in the study eye were enrolled in Cohort I, four of whom were transplanted with 200,000 stem cells, followed by four transplanted with one million cells. Seven patients with less severe BCVA of 20/320 to 20/100
in the study eye were enrolled in Cohort II and underwent a transplant with one million cells. In June 2014, we announced that interim results from this study show a 70 percent reduction in the rate of geographic atrophy (GA) as compared to the
control eye and a 65 percent reduction in the rate of GA as compared to the expected natural history of the disease following a single dose of the Company&#146;s proprietary HuCNS-SC&reg; human neural stem cells. In addition to these initial
efficacy findings, the Phase I/II trial has also demonstrated a favorable safety profile. Final results from this study are expected to be released mid-2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We previously completed a Phase I clinical trial in infantile and late infantile neuronal ceroid lipofuscinosis (NCL), which showed that our
HuCNS-SC cells were well tolerated and non-tumorigenic, and that there was evidence of engraftment and long-term survival of the transplanted HuCNS-SC cells. In October 2013, the results of a four-year, long-term follow up study of the patients from
the initial Phase I study showed there were no long-term safety or tolerability issues associated with the cells up to five years post-transplantation. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2013, we entered into an agreement with the California Institute for Regenerative
Medicine (CIRM) under which CIRM will provide up to approximately $19.3 million as a forgivable loan, in accordance with mutually agreed upon terms and conditions and CIRM regulations. The CIRM loan will help fund preclinical development of our
HuCNS-SC cells for Alzheimer&#146;s disease. We received an initial disbursement of $3.8 million under the CIRM Loan Agreement in July 2013, and a subsequent disbursement of $3.8 million in January 2014. For a brief description of our significant
therapeutic research and development programs see Overview &#147;Research and Development Programs&#148; in the Business Section of Part I, Item&nbsp;1 of our <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended
December&nbsp;31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also engaged in developing and commercializing applications of our technologies to enable research, which
we believe represent current and nearer-term commercial opportunities. Our portfolio of technologies includes cell technologies relating to embryonic stem cells, induced pluripotent stem (iPS) cells, and tissue-derived (adult) stem cells; expertise
and infrastructure for providing cell-based assays for drug discovery; a cell culture products and antibody reagents business; and an intellectual property portfolio with claims relevant to cell processing, reprogramming and manipulation, as well as
to gene targeting and insertion. Many of these enabling technologies were acquired in April 2009 as part of our acquisition of the operations of Stem Cell Sciences Plc (SCS). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not derived any revenue or cash flows from the sale or commercialization of any products except for license revenue for certain of our
patented technologies and sales of products for use in stem cell research. As a result, we have incurred annual operating losses since inception and expect to incur substantial operating losses in the future. Therefore, we are dependent upon
external financing, such as from equity and debt offerings, to finance our operations. Before we can derive revenue or cash inflows from the commercialization of any of our therapeutic product candidates, we will need to: (i)&nbsp;conduct
substantial in vitro testing and characterization of our proprietary cell types, (ii)&nbsp;undertake preclinical and clinical testing for specific disease indications; (iii)&nbsp;develop, validate and scale-up manufacturing processes to produce
these cell-based therapeutics, and (iv)&nbsp;obtain required regulatory approvals. These steps are risky, expensive and time consuming. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate
Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are incorporated in Delaware. Our principal executive offices are located at 7707 Gateway Blvd., Suite 140, Newark,
California 94560 and our telephone number is (510)&nbsp;456-4000. Our website is located at www.stemcellsinc.com. We have not incorporated by reference into this prospectus supplement or the accompanying prospectus the information in, or that can be
accessed through, our website, and you should not consider it to be a part of this prospectus supplement or the accompanying prospectus. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary contains basic information about the offering and is not intended to be complete. It does not contain all the information that may be
important to you. For a more complete understanding of the securities we are offering, you should read the section entitled &#147;Description of Securities.&#148; </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Issuer</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">StemCells, Inc.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Securities offered</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">11,299,435 units, with each unit consisting of one share of common stock and a warrant to purchase 0.85 shares of common stock, at a price per unit equal to $1.77. Each warrant will first be exercisable six months from the date of
issuance at an initial exercise price of $2.17 per share.&nbsp;The warrants are non-transferable and will expire thirteen months from the date of issuance.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Common stock to be outstanding after this offering</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">68,112,722 shares, excluding the shares underlying the warrants offered hereby.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Use of Proceeds</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">We intend to use net proceeds of this offering for general corporate purposes, including working capital, product development and capital expenditures. We may also use the net proceeds of this offering for acquisitions and other
strategic purposes, although we do not currently have any plans to do so. See &#147;Use of Proceeds.&#148;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Risk Factors</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Your investment in our securities involves substantial risks. You should consider the &#147;Risk Factors&#148; and the &#147;Note Regarding Forward-Looking Statements&#148; included and incorporated by reference in this prospectus
supplement and the accompanying prospectus, including the risk factors incorporated by reference from our filings with the SEC.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>NASDAQ ticker symbol</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">STEM</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock shown above to be outstanding after this offering is based on the 56,813,287 shares
outstanding as of June&nbsp;30, 2014 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">9,492,787 shares of our common stock that have been reserved for issuance upon exercise of the warrants offered by this prospectus supplement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">375,670 shares of our common stock subject to options outstanding as of June&nbsp;30, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,137,440 shares of our common stock subject to outstanding restricted stock units as of June&nbsp;30, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">10,015,497 shares of our common stock that have been reserved for issuance in connection with future grants under our stock option plans as of June&nbsp;30, 2014; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">14,207,426 shares of our common stock that have been reserved for issuance upon exercise of outstanding warrants as of June&nbsp;30, 2014. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read and carefully consider and evaluate the &#147;Risk Factors&#148; and &#147;Note Regarding Forward-Looking Statements&#148; included and
incorporated by reference in this prospectus and any applicable prospectus supplement, including the risk factors under the heading &#147;Item 1A. Risk Factors&#148; incorporated by reference from our Annual Report on Form 10-K for the year ended
December&nbsp;31, 2013, as updated by our other filings with the Securities and Exchange Commission (the &#147;SEC&#148;) pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;), filed after such annual report. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us, or that we currently deem immaterial, may also impair our business operations. If any of
these risks were to occur, our business, financial condition, or results of operations would likely suffer. In that event, the trading price of our common stock could decline, and you could lose all or part of your investment. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of the units offered by this prospectus supplement will be approximately $18.7&nbsp;million, after deducting
the placement agent fees and estimated offering expenses payable by us and excluding the proceeds, if any, of the warrants issued in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
intend to use the net proceeds of this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used
for the acquisition of businesses, products and technologies that are complementary to ours, or for other strategic purposes, although we have no current understandings, commitments or agreements to do so. Pending use of the net proceeds, we intend
to invest the net proceeds in short-term, interest-bearing, investment-grade securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_6"></A>PRICE RANGE OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock trades on The Nasdaq Global Market under the symbol &#147;STEM.&#148; The following table sets forth, for the periods indicated, the high and
low intraday sales prices per share of our common stock as reported by The Nasdaq Global Market. These prices do not include retail markups, markdowns or commissions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">High</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Low</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal year ending December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal year ending December&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal year ending December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The last reported sales price of our common stock on The Nasdaq Global Market on July&nbsp;14, 2014 was $2.02 per share. As of
June 30, 2014, there were outstanding 56,813,287 shares of our common stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our common stock. We anticipate that we will continue to retain our earnings, if any, for use in the
operation of our business. Accordingly, we do not expect to pay any cash dividends on our common stock for the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, you will experience dilution to the extent of the difference between the price per share you pay in this offering and the
net tangible book value per share of our common stock immediately after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of March&nbsp;31, 2014 was
approximately $3.7&nbsp;million, or $0.07 per share of common stock. Net tangible book value per share is equal to our total tangible assets minus total liabilities, all divided by the number of shares of common stock outstanding as of
March&nbsp;31, 2014. Assuming we sell 11,299,435&nbsp;shares of common stock at an offering price of $1.77 per share, and after deducting our estimated offering expenses payable by us, our as adjusted net tangible book value would have been
approximately $22.3&nbsp;million, or approximately $0.34 per share of common stock, as of March&nbsp;31, 2014. This represents an immediate increase in net tangible book value of approximately $0.27 per share to existing stockholders and an
immediate dilution of approximately $1.43 per share to new investors. The following table illustrates this calculation on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price for one share of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of March&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to the offering</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above illustration of dilution per share to investors participating in this offering assumes no exercise of the warrants offered by this prospectus
supplement, outstanding options to purchase our common stock or outstanding warrants to purchase shares of our common stock. The exercise of outstanding options and warrants having an exercise price less than the offering price will increase
dilution to new investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock shown above to be outstanding after this offering is based on the 56,813,287 shares
outstanding as of June&nbsp;30, 2014 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">9,492,787 shares of our common stock that have been reserved for issuance upon exercise of the warrants offered by this prospectus supplement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">375,670 shares of our common stock subject to options outstanding as of June&nbsp;30, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,137,440 shares of our common stock subject to outstanding restricted stock units as of June&nbsp;30, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">10,015,497 shares of our common stock that have been reserved for issuance in connection with future grants under our stock option plans as of June&nbsp;30, 2014; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">14,207,426 shares of our common stock that have been reserved for issuance upon exercise of outstanding warrants as of June&nbsp;30, 2014. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_9"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are offering units, each unit consisting of one share of our common stock and a warrant to purchase 0.85 of a share of our common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The units will not be issued or certificated. The shares of common stock and the warrants that we are issuing are immediately separable
and will be issued separately. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The material terms and provisions of our common stock are described under the caption &#147;Description of Common Stock&#148; starting on
page&nbsp;7 of the accompanying prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The warrants offered in this offering will be issued pursuant to a securities purchase agreement between each of the purchasers and us. You
should review the forms of securities purchase agreement and warrants, which will be filed as exhibits to a Current Report on Form 8-K filed with the SEC in connection with this offering, for a complete description of the terms and conditions
applicable to the warrants. The following is a brief summary of the material attributes and characteristics of the warrants and is subject in all respects to the provisions contained in such warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exercisability</I>. The warrants will first be exercisable six months from the date of issuance and will expire at the close of business on
the date that is thirteen months from the date of issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering
the issuance of the shares of common stock underlying the warrants under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) is effective and available for the issuance of such shares, or an exemption from registration under the
Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares
of common stock underlying the warrants under the Securities Act is not then effective or available, the holder may only exercise the warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of
shares of common stock determined according to the formula set forth in the warrant. No fractional shares or scrip representing fractional shares of common stock will be issued in connection with the exercise of a warrant. In lieu of fractional
shares, we may, at our election, pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exercise Limitation</I>. A holder will not have the right to exercise any portion of the warrant if the holder (together with its
affiliates) would beneficially own in excess of 4.99% of the number of shares of our stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However,
any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days&#146; prior notice from the holder to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exercise Price</I>. The initial exercise price per share of common stock purchasable upon exercise of the warrants is $2.17&nbsp;per share
of common stock. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any
distributions of assets, including cash, stock or other property to our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. The warrants and all rights
thereunder are not transferable, except to a legal successor in interest to the holder and to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Exchange Listing</I>. We do
not plan to apply to list the warrants on the OTCQB, any national securities exchange or any other nationally recognized trading system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Fundamental Transactions</I>. In the event of a fundamental transaction, as described in the warrants and generally including any
reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the holders of the
warrants will be entitled to receive, at the option of the holder, upon exercise of the warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such
fundamental transaction </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Rights as a Stockholder</I>. Except as otherwise provided in the warrants or by virtue of such holder&#146;s
ownership of shares of our common stock, the holder of a warrant does not have the rights or privileges of a holder of our common stock, including any voting rights or dividends until the holder exercises the warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, we entered into a letter agreement with Ascendiant to act as our financial advisor and placement agent in connection with
this offering. Ascendiant has agreed to use its &#147;best efforts&#148; to, among other things, arrange for the sale of the securities offered by this prospectus supplement, but Ascendiant is not obligated to purchase nor place any of the
securities offered by this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the letter agreement, we agreed to pay a placement fee to Ascendiant equal to 6.0% of the
total gross proceeds received by us in this offering payable at the closing, and an additional fee of up to 6.0% of the gross cash proceeds received by us from the exercise of any warrant sold by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total placement fee we will pay to Ascendiant in connection with the sale of the securities offered hereby, but
excluding the additional placement fee due and payable by us to Ascendiant upon exercise of the warrants offered hereby. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.1062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also agreed to reimburse the placement agent for its reasonable legal fees in connection with this offering in an
amount not to exceed $30,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a securities purchase agreement directly with the investors in this offering for the sale of the
securities offered by this prospectus supplement. The securities purchase agreement contains customary representations, warranties and covenants for transactions of this type. These representations, warranties and covenants were made solely for
purposes of the securities purchase agreement and should not be relied upon by any of our investors who are not parties to the agreement, nor should any such investor rely upon any descriptions thereof as characterizations of the actual state of
facts or condition. Such investors are not third party beneficiaries under the securities purchase agreement. Any investor has the option, upon written notice to us and the other investors party to the securities purchase agreement, to terminate
such investor&#146;s obligations thereunder if the closing is not consummated by July&nbsp;18, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is a brief summary of the material provisions
of the securities purchase agreement and does not purport to be a complete statement of its terms and conditions. A copy of the securities purchase agreement will be filed with the SEC and incorporated by reference into the registration statement of
which this prospectus supplement forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify Ascendiant and certain other affiliates and control persons of Ascendiant
against certain liabilities relating to or arising out of Ascendiant&#146;s activities under the engagement letter. We have also agreed to contribute to payments Ascendiant may be required to make in respect of such liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ascendiant may be deemed to be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act, and any commissions received by it might be
deemed to be underwriting discounts or commissions under the Securities Act.&nbsp;As an underwriter, Ascendiant would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation,
Rule&nbsp;415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act.&nbsp;These rules and regulations may limit the timing of purchases and sales of shares of common stock and warrants by Ascendiant acting as
principal.&nbsp;Under these rules and regulations, Ascendiant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not engage in any stabilization activity in connection with our securities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the
distribution. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently anticipate that the closing of the sale of the shares of common stock and warrants offered pursuant to this
prospectus supplement will take place on or before July&nbsp;18, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts, will pass upon the validity of the securities offered by this prospectus supplement and the
accompanying prospectus. Ascendiant is being represented in connection with this offering by Ellenoff Grossman&nbsp;&amp; Schole, LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly, and special reports, proxy statements, and other information with the SEC. These documents are on file with the SEC
under file number 000-19871. You may read and copy any document we file at the SEC at 100 F Street, N.E., Washington, D.C., 20549. You can request copies of these documents by contacting the SEC and paying a fee for the copying cost. Please call the
SEC at 1-800-SEC-0330 for further information. Our SEC filings are also available to the public from the SEC&#146;s website at www.sec.gov. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc759111_13"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 filed by us with the SEC. This
prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. Statements contained in
this prospectus supplement, the accompanying prospectus or the documents incorporated by reference into this prospectus supplement or the accompanying prospectus as to the contents of any contract or other document referred to are not necessarily
complete and in each instance reference is made to the copy of that contract or other document filed with the SEC. For further information about us and the securities offered by this prospectus supplement, we refer you to the registration statement
and its exhibits and schedules which may be obtained as described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the
information contained in documents that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus
supplement and the accompanying prospectus, and information in documents that we file later with the SEC will automatically update and supersede information in this prospectus supplement and the accompanying prospectus. We incorporate by reference
the documents listed below into this prospectus supplement, and any future filings made by us with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act until the offering of all the securities by this prospectus supplement is
completed, including all filings made after the date of this prospectus supplement. We hereby incorporate by reference the documents listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2013; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed on February&nbsp;13, 2014,&nbsp;April&nbsp;17, 2014,&nbsp;May&nbsp;23, 2014,&nbsp;June&nbsp;13, 2014,&nbsp;July&nbsp;8, 2014 and July&nbsp;15, 2014; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form 8-A filed August&nbsp;3, 1998, under the Exchange Act, including any amendment or report filed for the purpose of updating such
description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide each person to whom this prospectus supplement is delivered a copy of all of the information
that has been incorporated by reference in this prospectus supplement or the accompanying prospectus but not delivered with this prospectus supplement and the accompanying prospectus. The public may read and copy any materials that the Company files
with the SEC at the SEC at 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information on access to such information by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy and information
statements and other information regarding issuers that file electronically with the SEC at http://www.sec.gov. You may also obtain copies of these filings, at no cost, through the &#147;Investor Relations&#148; section of our website
(www.stemcellsinc.com), and you may request copies of these filings, at no cost, by writing or telephoning us at: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">StemCells, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7707 Gateway Blvd., Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Newark, CA 94560 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: (510)&nbsp;456-4000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">e-mail: irpr@stemcellsinc.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>STEMCELLS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer to the public, from time to time, in one or more series or issuances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">shares of our preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warrants to purchase shares of our common stock, preferred stock and/or debt securities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">debt securities consisting of debentures, notes or other evidences of indebtedness. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to this prospectus. The prospectus supplement may also add, update or
change information contained in this prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied by the applicable prospectus supplement. You should read both this prospectus and any prospectus supplement
together with additional information described under the heading &#147;Where You Can Find More Information&#148; before you make your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will sell these securities directly to our stockholders or to purchasers or through agents on our behalf or through underwriters or dealers
as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions or
discounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Capital Market under the symbol &#147;STEM.&#148; On December 24, 2013, the closing
price of our common stock was $1.31. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves certain risks. Please carefully consider &#147;<A HREF="#tx655007_2">Risk Factors</A>&#148; on page 3
and other information included and incorporated by reference in this prospectus, and in any applicable prospectus supplement, for a discussion of the factors you should consider carefully before deciding to purchase our securities. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is January&nbsp;8, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_3">Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_5">Ratio of Earnings to Fixed Charges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_6">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_7">Description of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_8">Description of Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_9">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_10">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_12">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_13">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx655007_14">Incorporation of Certain Documents by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission
(the &#147;SEC&#148;) utilizing a &#147;shelf&#148; registration process. Under this shelf process, we may sell different types of securities described in this prospectus in one or more offerings. This prospectus provides you with a general
description of the securities we may offer. Each time we offer securities, we will provide a prospectus supplement and attach it to this prospectus. The prospectus supplement will contain specific information about the nature of the persons offering
securities and the terms of the securities being offered at that time. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement, including
all documents incorporated herein by reference, together with additional information described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents By Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not contain all of the information that is in the registration statement. We omitted certain parts of the registration
statement from this prospectus as permitted by the SEC. We refer you to the registration statement and its exhibits for additional information about us and the securities that may be sold under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this prospectus to &#147;StemCells,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; mean
StemCells, Inc. and its subsidiaries unless we state otherwise or the context otherwise requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information
contained or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an
offer to sell these securities in any jurisdiction where the offer is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or the time
of any sale of our securities. Our business, financial condition, results of operations, and prospects may have changed since such date. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_1"></A>P<A NAME="supptoc759111_14"></A>ROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of selected information contained elsewhere or incorporated by reference in this prospectus. It does not contain
all of the information that you should consider before buying our securities. You should read this entire prospectus carefully, especially the section entitled &#147;Risk Factors&#148; and the consolidated financial statements and the notes to the
consolidated financial statements incorporated by reference.</I> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are engaged in researching, developing, and commercializing cell-based therapeutics and enabling tools and technologies for stem cell-based
research and drug discovery and development. Our research and development (R&amp;D) programs are primarily focused on identifying and developing potential cell-based therapeutics which can either restore or support organ function. In particular,
since we relocated our corporate headquarters to California in 1999, our R&amp;D efforts have been directed at refining our methods for identifying, isolating, culturing, and purifying the human neural stem cell and developing this cell as potential
cell-based therapeutics for the central nervous system (CNS). Our HuCNS-SC&reg; cells (purified human neural stem cells) are currently in clinical development for several indications &#151; chronic spinal cord injury, dry age-related macular
degeneration (AMD) and Pelizeaus-Merzbacher disease (PMD), which is a myelination disorder in the brain. We are also conducting preclinical research to evaluate HuCNS-SC cells in Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2012, we published in <I>Science Translational Medicine</I>, a peer-reviewed journal, the data from our four-patient Phase I
clinical trial in PMD, which showed preliminary evidence of durable and progressive donor-derived myelination in all four patients. In addition, there were measurable gains in neurological function in three of the four patients, with the fourth
patient clinically stable. We are conducting a Phase I/II clinical trial for the treatment of chronic spinal cord injury, which represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord
injury. This trial is being conducted in Switzerland, Canada, and the United States. Data from the first three patients demonstrated a favorable safety profile and multi-segment gains in sensory function in two of the three patients 12 months after
transplantation of HuCNS-SC cells compared to pre-transplant baselines; the third patient remained stable. As of November 2013, a total of eight patients have been dosed with our HuCNS-SC cells in this trial. We are also conducting a Phase I/II
clinical trial in dry AMD at two trial sites in the United States, and as of November 2013, have enrolled and dosed a total of seven patients with our HuCNS-SC cells in this trial. We previously completed a Phase I clinical trial in infantile and
late infantile neuronal ceroid lipofuscinosis (NCL), which showed that our HuCNS-SC cells were well tolerated and non-tumorigenic, and that there was evidence of engraftment and long-term survival of the transplanted HuCNS-SC cells. In October 2013,
the results of a four-year, long-term follow up study of the patients from the initial Phase I study showed there were no long-term safety or tolerability issues associated with the cells up to five years post-transplantation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2013, we entered into an agreement with the California Institute for Regenerative Medicine (CIRM) under which CIRM will provide up to
approximately $19.3 million as a forgivable loan, in accordance with mutually agreed upon terms and conditions and CIRM regulations. The CIRM loan will help fund preclinical development of our HuCNS-SC cells for Alzheimer&#146;s disease. In July
2013, we received an initial disbursement of $3.8 million under the CIRM Loan Agreement. For a brief description of our significant therapeutic research and development programs see Overview &#147;Research and Development Programs&#148; in the
Business Section of Part I, Item&nbsp;1 of our Form 10-K for the year ended December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are also engaged in developing and
commercializing applications of our technologies to enable research, which we believe represent current and nearer-term commercial opportunities. Our portfolio of technologies includes cell technologies relating to embryonic stem cells, induced
pluripotent stem (iPS) cells, and tissue-derived (adult) stem cells; expertise and infrastructure for providing cell-based assays for drug discovery; a cell culture products and antibody reagents business; and an intellectual property portfolio with
claims relevant to cell processing, reprogramming and manipulation, as well as to gene targeting and insertion. Many of these enabling technologies were acquired in April 2009 as part of our acquisition of the operations of Stem Cell Sciences Plc
(SCS). </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not derived any revenue or cash flows from the sale or commercialization of any
products except for license revenue for certain of our patented technologies and sales of products for use in stem cell research. As a result, we have incurred annual operating losses since inception and expect to incur substantial operating losses
in the future. Therefore, we are dependent upon external financing, such as from equity and debt offerings, to finance our operations. Before we can derive revenue or cash inflows from the commercialization of any of our therapeutic product
candidates, we will need to: (i)&nbsp;conduct substantial in vitro testing and characterization of our proprietary cell types, (ii)&nbsp;undertake preclinical and clinical testing for specific disease indications; (iii)&nbsp;develop, validate and
scale-up manufacturing processes to produce these cell-based therapeutics, and (iv)&nbsp;obtain required regulatory approvals. These steps are risky, expensive and time consuming. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
incorporated in Delaware. Our principal executive offices are located at 7707 Gateway Blvd., Suite 140, Newark, California 94560 and our telephone number is (510)&nbsp;456-4000. Our website is located at www.stemcellsinc.com. We have not
incorporated by reference into this prospectus supplement or the accompanying prospectus the information in, or that can be accessed through, our website, and you should not consider it to be a part of this prospectus supplement or the accompanying
prospectus. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_2"></A>R<A NAME="supptoc759111_15"></A>ISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should consider the &#147;Risk Factors&#148; included and incorporated by reference in this prospectus and any applicable prospectus
supplement, including the risk factors incorporated by reference from our most recent Annual Report on Form 10-K, as updated by our Quarterly Reports on Form 10-Q and our other filings with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of
the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) filed after such annual report. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us, or that we currently
deem immaterial, may also impair our business operations. If any of these risks were to occur, our business, financial condition, or results of operations would likely suffer. In that event, the trading price of our common stock could decline, and
you could lose all or part of your investment. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_3"></A>N<A NAME="supptoc759111_16"></A>OTE REGARDING
FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated in this prospectus by reference may contain
&#147;forward-looking statements&#148;. Except for strictly historical information contained herein, matters discussed in this report constitute forward-looking statements. Generally, these statements may be identified by the use of forward-looking
words or phrases such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;look forward,&#148; &#147;may,&#148; &#147;planned,&#148; &#147;potential,&#148;
&#147;should,&#148; &#147;will,&#148; and &#147;would,&#148; and similar terms. These forward-looking statements reflect our current expectations and are based upon currently available data. The Private Securities Litigation Reform Act of 1995
provides a &#147;safe harbor&#148; for such forward-looking statements. In order to comply with the terms of the safe harbor, we note that a variety of factors could cause actual results and experience to differ materially from the anticipated
results or other expectations expressed in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such statements include, without limitation, all statements as
to expectation or belief and statements as to our future results of operations; the progress of our research, product development and clinical programs; the need for, and timing of, additional capital and capital expenditures; partnering prospects;
costs of manufacturing products; the protection of, and the need for, additional intellectual property rights; effects of regulations; the need for additional facilities; and potential market opportunities. Our actual results may vary materially
from those contained in such forward-looking statements because of risks to which we are subject, including the fact that additional trials will be required to confirm the safety and demonstrate the efficacy of our HuCNS-SC cells for the treatment
of any disease or disorder; uncertainty as to whether the U.S. Food and Drug Administration (FDA), Swissmedic, or other regulatory authorities will permit us to continue with clinical testing of proposed products despite the novel and unproven
nature of our technologies; the risk that our clinical trials or studies could be substantially delayed beyond their expected dates or cause us to incur substantial unanticipated costs; uncertainties in our ability to obtain the capital resources
needed to continue our current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; the uncertainty regarding our ability to obtain a corporate partner or
partners, if needed, to support the development and commercialization of our potential cell-based therapeutics products; the uncertainty regarding the outcome of our clinical trials or studies we may conduct in the future; the uncertainty regarding
the validity and enforceability of our issued patents; the risk that we may not be able to manufacture additional master and working cell banks when needed; the uncertainty as to whether the Company&#146;s preclinical studies will be replicated in
humans; the uncertainty whether any products that may be generated in our cell-based therapeutics programs will prove clinically safe and effective; the uncertainty of whether we will achieve significant revenue from product sales or become
profitable; obsolescence of our technologies; competition from third parties; intellectual property rights of third parties; litigation risks; and other risks to which we are subject. All forward-looking statements attributable to us or to persons
acting on our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth in &#147;Risk Factors&#148; in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus represent our estimates as of the date of this prospectus. We specifically disclaim
any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing our estimates or views as of any date subsequent to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_4"></A>U<A NAME="supptoc759111_17"></A>SE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities
covered by this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, acquisitions of new technologies or businesses, and investments.
Additional information on the use of net proceeds from the sale of securities covered by this prospectus may be set forth in the prospectus supplement relating to the specific offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_5"></A>R<A NAME="supptoc759111_18"></A>ATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we offer debt securities and/or preference equity securities under this prospectus, then we will, if required at that time, provide a ratio
of earnings to fixed charges and/or ratio of combined fixed charges and preference dividends to earnings, respectively, in the applicable prospectus supplement for such offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_6"></A>P<A NAME="supptoc759111_19"></A>LAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may sell securities in any of the ways described below, including any combination thereof: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to or through underwriters or dealers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through one or more agents; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to purchasers or to a single purchaser. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be
effected from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at a fixed price, or prices, which may be changed from time to time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of
the securities and any applicable restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will
describe the terms of the offering of the securities, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of any underwriters, dealers or agents and the amounts of securities underwritten or purchased by each of them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the initial public offering price of the securities and the proceeds to us and any discounts, commissions or concessions allowed or reallowed or paid to dealers; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchanges on which the securities may be listed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any initial public offering
price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. In no event will any underwriter or dealer receive fees, commissions and markups, which, in the aggregate, would exceed eight percent of
the price of the securities being registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Only the agents or underwriters named in the prospectus supplement are agents or
underwriters in connection with the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may authorize underwriters, dealers or other persons acting as our
agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an amount not less
than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom the contracts, when authorized, may be made include
commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will be subject
only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions we pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Agents, underwriters and other third parties described above may be entitled to indemnification by us against certain civil liabilities,
including liabilities under the Securities Act, or to contribution with respect to payments which the agents or underwriters may be required to make in respect thereof. Agents, underwriters and such other third parties may be customers of, engage in
transactions with, or perform services for us in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">One or more firms, referred to as &#147;remarketing firms,&#148; may also offer or sell the
securities, if the prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as our agents. These remarketing firms will offer or sell the
securities in accordance with the terms of the securities. The prospectus supplement will identify any remarketing firm and describe the terms of its agreement, if any, with us and the remarketing firm&#146;s compensation. Remarketing firms may be
deemed to be underwriters in connection with the securities they remarket. Remarketing firms may be entitled under agreements that may be entered into with us to indemnification by us against certain civil liabilities, including liabilities under
the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters may use this prospectus and the accompanying prospectus supplement for offers and sales related to market-making
transactions in the securities. These underwriters may act as principal or agent in these transactions, and the sales will be made at prices related to prevailing market prices at the time of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a
national securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We can make no assurance as to the liquidity of, or the existence
of trading markets for, any of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain persons participating in this offering may engage in overallotment, stabilizing
transactions, short covering transactions and penalty bids in accordance with rules and regulations under the Exchange Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit
bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short
positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of
the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_7"></A>D<A NAME="supptoc759111_20"></A>ESCRIPTION OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of the terms of our common stock is subject to and qualified in its entirety by reference to our charter and by-laws,
copies of which are on file with the SEC as exhibits to previous SEC filings. Please refer to &#147;Where You Can Find More Information&#148; below for directions on obtaining these documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have authority to issue 225,000,000 shares of common stock. As of December 18, 2013 we had 55,137,668 shares of common stock outstanding.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock are
entitled to one vote per share on matters on which our stockholders vote. There are no cumulative voting rights. Holders of common stock are entitled to receive dividends, if declared by our board of directors, out of funds that we may legally use
to pay dividends. If we liquidate or dissolve, holders of common stock are entitled to share ratably in our assets once our debts and any liquidation preference owed to any then-outstanding preferred stockholders are paid. Our certificate of
incorporation does not provide the common stock with any redemption, conversion or preemptive rights. All shares of common stock that are outstanding as of the date of this prospectus and, upon issuance and sale, all shares we are offering by this
prospectus, will be fully-paid and nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock
is listed for quotation on the Nasdaq Capital Market under the symbol &#147;STEM.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_8"></A>D<A NAME="supptoc759111_21">
</A>ESCRIPTION OF PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have authority to issue 1,000,000 shares of undesignated preferred stock. As of December 18,
2013, no shares of our preferred stock were outstanding. The following summary of certain provisions of our preferred stock does not purport to be complete. You should refer to our restated certificate of incorporation and our amended and restated
by-laws, both of which are included as exhibits to the registration statement we have filed with the SEC in connection with this offering. The summary below is also qualified by provisions of applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, without stockholder approval, from time to time, to issue shares of preferred stock in series and may,
at the time of issuance, subject to Delaware law and our charter and by-laws, determine the rights, preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of any
dividend preferences of outstanding shares of preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of preferred stock may be entitled to receive a preference payment
in the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares of preferred stock may render more difficult or tend to
discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of incumbent management. Upon the affirmative vote of our board of directors, without stockholder approval,
we may issue shares of preferred stock with voting and conversion rights which could adversely affect the holders of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus
supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent required, this description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title and stated value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares offered, the liquidation preference per share and the purchase price; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the procedures for any auction and remarketing, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for a sinking fund, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for redemption, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any listing of the preferred stock on any securities exchange or market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price (or how it will be calculated) and conversion period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price (or how it will be calculated) and exchange period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting rights, if any, of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs of StemCells, Inc.; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or
winding up of StemCells, Inc. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preferred stock offered by this prospectus will, when issued, be fully paid and
nonassessable and will not have, or be subject to, any preemptive or similar rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for any series or class of preferred stock will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_9"></A>D<A NAME="supptoc759111_22"></A>ESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase shares of our common stock, preferred stock and/or debt securities in one or more series together with other
securities or separately, as described in the applicable prospectus supplement. Below is a description of certain general terms and provisions of the warrants that we may offer. Particular terms of the warrants will be described in the warrant
agreements and the prospectus supplement to the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will contain, where applicable, the
following terms of, and other information relating to, the warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the specific designation and aggregate number of, and the price at which we will issue, the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency or currency units in which the offering price, if any, and the exercise price are payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation, amount and terms of the securities purchasable upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the exercise price for shares of our common stock and the number of shares of common stock to be received upon exercise of the warrants; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the exercise price for shares of our preferred stock, the number of shares of preferred stock to be received upon exercise, and a description of that series of our preferred stock; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the exercise price for our debt securities, the amount of debt securities to be received upon exercise, and a description of that series of debt securities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on
which you may exercise the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will
correspond to the form of the unit and of any security included in that unit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any applicable material U.S. federal income tax consequences; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date from and after which the warrants and the common stock, preferred stock and/or debt securities will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information with respect to book-entry procedures, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anti-dilution provisions of the warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any redemption or call provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the warrants are to be sold separately or with other securities as parts of units; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_10"></A>D<A NAME="supptoc759111_23">
</A>ESCRIPTION OF DEBT SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities offered by this prospectus and any accompanying prospectus
supplement under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those stated in the indenture and those made part of the indenture by
reference to the Trust Indenture Act of 1939, as in effect on the date of the indenture. We have filed a copy of the form of indenture as an exhibit to the registration statement in which this prospectus is included. The indenture will be subject to
and governed by the terms of the Trust Indenture Act of 1939. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer under this prospectus up to an aggregate principal amount of
$100,000,000 in debt securities; or if debt securities are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may be sold for an initial public offering price of up to $100,000,000.
Unless otherwise specified in the applicable prospectus supplement, the debt securities will represent direct, unsecured obligations of StemCells, Inc. and will rank equally with all of our other unsecured indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following statements relating to the debt securities and the indenture are summaries, qualified in their entirety to the detailed
provisions of the indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will
describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will set forth, to the extent required, the following terms of the debt securities in respect of which the
prospectus supplement is delivered: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate principal amount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit on the aggregate principal amount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates on which principal is payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such rate or rates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates from which interest, if any, will be payable and any regular record date for the interest payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the place or places where principal and, if applicable, premium and interest, is payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any integral multiple of that number; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities are to be issuable in the form of certificated debt securities (as described below) or global debt securities (as described below); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if other than the principal amount of the debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of denomination; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation of the currency, currencies or currency units in which payment of principal and, if applicable, premium and interest, will be made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or more currencies or currency units other than the currency of denomination, the manner in which the
exchange rate with respect to such payments will be determined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or
financial index, then the manner in which such amounts will be determined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions, if any, relating to any collateral provided for such debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any addition to or change in the covenants and/or the acceleration provisions described in this prospectus or in the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any events of default, if not otherwise described below under &#147;Events of Default&#148;; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, for conversion into or exchange for shares of common stock or preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to other indebtedness of StemCells, Inc. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue discount debt securities that provide for an amount less than the stated principal
amount to be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount debt securities or
debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do, we
will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange and/or Conversion Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
issue debt securities which can be exchanged for or converted into shares of common stock or preferred stock. If we do, we will describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt
securities that will be represented by either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;book-entry securities,&#148; which means that there will be one or more global securities registered in the name of a depositary or a nominee of a depositary; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;certificated securities,&#148; which means that they will be represented by a certificate issued in definitive registered form. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will specify in the prospectus supplement applicable to a particular offering whether the debt securities offered will be book-entry or
certificated securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificated Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold certificated debt securities, you may transfer or exchange such debt securities at the trustee&#146;s office or at the paying
agent&#146;s office or agency in accordance with the terms of the indenture. You will not be charged a service charge for any transfer or exchange of certificated debt securities but may be required to pay an amount sufficient to cover any tax or
other governmental charge payable in connection with such transfer or exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt
securities and of the right to receive the principal of, premium, and/or interest, if any, on the certificated debt securities only by surrendering the certificate representing the certificated debt securities and having us or the trustee issue a
new certificate to the new holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we decide to issue debt securities in the form of one or more global securities, then we will register the global securities in the name of
the depositary for the global securities or the nominee of the depositary, and the global securities will be delivered by the trustee to the depositary for credit to the accounts of the holders of beneficial interests in the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will describe the specific terms of the depositary arrangement for debt securities of a series that are issued in
global form. None of our company, the trustee, any payment agent or the security registrar will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in a global
debt security or for maintaining, supervising or reviewing any records relating to these beneficial ownership interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not have any covenants or other provisions providing for a put or increased interest or otherwise that would afford holders
of debt securities additional protection in the event of a recapitalization transaction, a change of control of StemCells, Inc., or a highly leveraged transaction. If we offer any covenants or provisions of this type with respect to any debt
securities covered by this prospectus, we will describe them in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in this prospectus or a prospectus supplement, the debt securities will not have the benefit of any covenants that
limit or restrict our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed in the indenture that we will not consolidate with or merge into any other person or convey, transfer, sell or lease our
properties and assets substantially as an entirety to any person, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the person formed by the consolidation or into or with which we are merged or the person to which our properties and assets are conveyed, transferred, sold or leased, is a corporation organized and existing under the
laws of the U.S., any state or the District of Columbia or a corporation or comparable legal entity organized under the laws of a foreign jurisdiction and, if we are not the surviving person, the surviving person has expressly assumed all of our
obligations, including the payment of the principal of and, premium, if any, and interest on the debt securities and the performance of the other covenants under the indenture; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">immediately before and immediately after giving effect to the transaction, no event of default, and no event which, after notice or lapse of time or both, would become an event of default, has occurred and is continuing
under the indenture. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, the following events will be events of default under the indenture with
respect to debt securities of any series: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we fail to pay any principal or premium, if any, when it becomes due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we fail to pay any interest within 30&nbsp;days after it becomes due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we fail to comply with any other covenant in the debt securities or the indenture for 60&nbsp;days after written notice specifying the failure from the trustee or the holders of not less than 25% in aggregate principal
amount of the outstanding debt securities of that series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain events involving bankruptcy, insolvency or reorganization of StemCells, Inc. or any of our significant subsidiaries. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee may withhold notice to the holders of the debt securities of any series of any default, except in payment of principal of or
premium, if any, or interest on the debt securities of a series, if the trustee considers it to be in the best interest of the holders of the debt securities of that series to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default (other than an event of default resulting from certain events of bankruptcy, insolvency or reorganization) occurs, and
is continuing, then the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of any series may accelerate the maturity of the debt securities. If this happens, the entire principal amount, plus
the premium, if any, of all the outstanding debt securities of the affected series plus accrued interest to the date of acceleration will be immediately due and payable. At any time after the acceleration, but before a judgment or decree based on
such acceleration is obtained by the trustee, the holders of a majority in aggregate principal amount of outstanding debt securities of such series may rescind and annul such acceleration if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all events of default (other than nonpayment of accelerated principal, premium or interest) have been cured or waived; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all lawful interest on overdue interest and overdue principal has been paid; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rescission would not conflict with any judgment or decree. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the
acceleration occurs at any time when we have outstanding indebtedness which is senior to the debt securities, the payment of the principal amount of outstanding debt securities may be subordinated in right of payment to the prior payment of any
amounts due under the senior indebtedness, in which case the holders of debt securities will be entitled to payment under the terms prescribed in the instruments evidencing the senior indebtedness and the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default resulting from certain events of bankruptcy, insolvency or reorganization occurs, the principal, premium and interest
amount with respect to all of the debt securities of any series will be due and payable immediately without any declaration or other act on the part of the trustee or the holders of the debt securities of that series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of a series will have the right to waive any existing default
or compliance with any provision of the indenture or the debt securities of that series and to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, subject to certain limitations specified in the
indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of any debt security of a series will have any right to institute any proceeding with respect to the indenture or
for any remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder gives to the trustee written notice of a continuing event of default; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the affected series make a written request and offer reasonable indemnity to the trustee to institute a proceeding as
trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee fails to institute a proceeding within 60&nbsp;days after such request; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of a majority in aggregate principal amount of the outstanding debt securities of the affected series do not give the trustee a direction inconsistent with such request during such 60-day period.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not, however, apply to a suit instituted for payment on debt securities of any series on or after the
due dates expressed in the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we and the trustee may, without the consent of holders of the debt securities of one or more series, amend the indenture or
the debt securities of one or more series, or supplement the indenture, for certain specified purposes, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide that the surviving entity following a change of control of StemCells, Inc. permitted under the indenture will assume all of our obligations under the indenture and debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for certificated debt securities in addition to uncertificated debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with any requirements of the SEC under the Trust Indenture Act of 1939; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to cure any ambiguity, defect or inconsistency, or make any other change that does not materially and adversely affect the rights of any holder; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to appoint a successor trustee under the indenture with respect to one or more series. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we and the trustee may, with the consent of holders of at least a majority in
principal amount of the outstanding series of debt securities, amend or supplement the indenture or the debt securities of such series, or waive compliance in a particular instance by us with any provision of the indenture or the debt securities. We
may not, however, without the consent of each holder affected by such action, modify or supplement the indenture or the debt securities or waive compliance with any provision of the indenture or the debt securities in order to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the amount of debt securities whose holders must consent to an amendment, supplement, or waiver to the indenture or such debt security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the rate of or change the time for payment of interest; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal of or change the stated maturity of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any debt security payable in money other than that stated in the debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the amount or time of any payment required or reduce the premium payable upon any redemption, or change the time before which no such redemption may be made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">waive a default in the payment of the principal of, premium, if any, or interest on the debt securities or a redemption payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">waive a redemption payment with respect to any debt securities or change any provision with respect to redemption of debt securities; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">take any other action otherwise prohibited by the indenture to be taken without the consent of each holder affected by the action. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture permits us, at any time, to elect to discharge our obligations with respect to one or more series of debt securities by following
certain procedures described in the indenture. These procedures will allow us either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to defease and be discharged from any and all of our obligations with respect to any debt securities except for the following obligations (which discharge is referred to as &#147;legal defeasance&#148;):
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) to register the transfer or exchange of such debt securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) to replace temporary or mutilated, destroyed, lost or stolen debt securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) to compensate and indemnify the trustee; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) to maintain an office or agency in respect of the debt securities and to hold monies for payment in trust; or </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to be released from our obligations with respect to the debt securities under certain covenants contained in the indenture, as well as any additional covenants which may be contained in the applicable supplemental
indenture (which release is referred to as &#147;covenant defeasance&#148;). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise either defeasance option,
we must deposit with the trustee or other qualifying trustee, in trust for that purpose: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">money; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. Government Obligations (as described below) or Foreign Government Obligations (as described below) which through the scheduled payment of principal and interest in accordance with their terms will provide money; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a combination of money and/or U.S. Government Obligations and/or Foreign Government Obligations sufficient in the written opinion of a nationally-recognized firm of independent accountants to provide money;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which in each case specified above, provides a sufficient amount to pay the principal of, premium, if any, and
interest, if any, on the debt securities of the series, on the scheduled due dates or on a selected date of redemption in accordance with the terms of the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, defeasance may be effected only if, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of either legal or covenant defeasance, we deliver to the trustee an opinion of counsel, as specified in the indenture, stating that as a result of the defeasance neither the trust nor the trustee will be
required to register as an investment company under the Investment Company Act of 1940; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of legal defeasance, we deliver to the trustee an opinion of counsel stating that we have received from, or there has been published by, the Internal Revenue Service a ruling to the effect that, or there has
been a change in any applicable federal income tax law with the effect that (and the opinion shall confirm that), the holders of outstanding debt securities will not recognize income, gain or loss for U.S. federal income tax purposes solely as a
result of such legal defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner, including as a result of prepayment, and at the same times as would have been the case if legal defeasance had not occurred;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of covenant defeasance, we deliver to the trustee an opinion of counsel to the effect that the holders of the outstanding debt securities will not recognize income, gain or loss for U.S. federal income tax
purposes as a result of covenant defeasance and will be subject to U.S. federal income tax on the same amounts, in the same manner and at the same times as would have been the case if covenant defeasance had not occurred; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain other conditions described in the indenture are satisfied. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with
our remaining obligations under the indenture and applicable supplemental indenture after a covenant defeasance of the indenture and applicable supplemental indenture, and the debt securities are declared due and payable because of the occurrence of
any undefeased event of default, the amount of money and/or U.S. Government Obligations and/or Foreign Government Obligations on deposit with the trustee could be insufficient to pay amounts due under the debt securities of the affected series at
the time of acceleration. We will, however, remain liable in respect of these payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;U.S. Government Obligations&#148;
as used in the above discussion means securities which are direct obligations of or non-callable obligations guaranteed by the United States of America for the payment of which obligation or guarantee the full faith and credit of the United States
of America is pledged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Foreign Government Obligations&#148; as used in the above discussion means, with respect to debt
securities of any series that are denominated in a currency other than U.S. dollars (1)&nbsp;direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is
pledged or (2)&nbsp;obligations of a person controlled or supervised by or acting as an agent or instrumentality of such government the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that government,
which in either case under clauses (1)&nbsp;or (2), are not callable or redeemable at the option of the issuer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will identify the trustee with respect to any series of debt securities in the prospectus supplement relating to the applicable debt
securities. You should note that if the trustee becomes a creditor of StemCells, Inc., the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in certain cases, or to realize on certain property
received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our affiliates. If, however, the trustee acquires any
&#147;conflicting interest&#148; within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of a majority in principal amount of the then outstanding debt securities of any series may direct the time, method and place of conducting any proceeding for exercising any remedy available to the trustee. If an event
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of default occurs and is continuing, the trustee, in the exercise of its rights and powers, must use the degree of care and skill of a prudent person in the conduct of his or her own affairs.
Subject to that provision, the trustee will be under no obligation to exercise any of its rights or powers under the indenture at the request of any of the holders of the debt securities, unless they have offered to the trustee reasonable indemnity
or security. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_11"></A>L<A NAME="supptoc759111_24"></A>EGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the securities offered hereby will be passed upon for us by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts.
The validity of any securities will be passed upon for any underwriters or agents by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_12"></A>E<A NAME="supptoc759111_25"></A>XPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audited financial statements incorporated by reference in this prospectus and elsewhere in the registration statement have been
incorporated by reference in reliance upon the report of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_13"></A>W<A NAME="supptoc759111_26"></A>HERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly, and special reports, proxy statements, and other information with the SEC. These documents are on file with the SEC
under file number 000-19871. You may read and copy any document we file at the SEC&#146;s public reference room at 100 F Street, N.E., Washington, D.C., 20549. You can request copies of these documents by contacting the SEC and paying a fee for the
copying cost. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Our SEC filings are also available to the public from the SEC&#146;s website at www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx655007_14"></A>I<A NAME="supptoc759111_27"></A>NCORPORATION OF CERTAIN DOCUMENTS BY
REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form S-3 filed by us with the SEC. This prospectus does not contain
all of the information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. Statements contained in this prospectus as to the contents of any contract or other document
referred to are not necessarily complete and in each instance reference is made to the copy of that contract or other document filed with the SEC. For further information about us and the securities offered by this prospectus, we refer you to the
registration statement and its exhibits and schedules which may be obtained as described herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate
by reference&#148; the information contained in documents that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part
of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information in this prospectus. We incorporate by reference the documents listed below into this prospectus, and any future
filings made by us with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act until the offering of all the securities by this prospectus is completed, including all filings made after the filing date of this initial registration
statement and prior to its effectiveness. We hereby incorporate by reference the documents listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2012, as amended; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, 2013,&nbsp;June&nbsp;30, 2013 and September&nbsp;30, 2013; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed on February&nbsp;13, 2013,&nbsp;March&nbsp;12, 2013,&nbsp;April&nbsp;11, 2013,&nbsp;June&nbsp;4, 2013,&nbsp;June&nbsp;10, 2013,&nbsp;August&nbsp;5, 2013, September&nbsp;12,
2013,&nbsp;October&nbsp;4, 2013, October&nbsp;30, 2013, November 14, 2013 (as amended) and December 23, 2013; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Definitive Proxy Statement on Schedule 14A filed on October&nbsp;31, 2013; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form 8-A filed August&nbsp;3, 1998, under the Exchange Act, including any amendment or report filed for the purpose of updating such
description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">We will provide each person to whom this prospectus is delivered a copy of all of the information that has
been incorporated by reference in this prospectus but not delivered with this prospectus. You may obtain copies of these filings, at no cost, through the &#147;Investor Relations&#148; section of our website (www.stemcellsinc.com), and you may
request copies of these filings, at no cost, by writing or telephoning us at: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">StemCells, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7707 Gateway Blvd., Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Newark, CA 94560 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention:
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone: (510)&nbsp;456-4000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">e-mail: <U>irpr@stemcellsinc.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The information contained on our website is not a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>11,299,435 Shares of Common Stock
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 9,604,520 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g759111suppbc_pg001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;14,
2014 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g759111suppbc_pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759111suppbc_pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+P#<`P$1``(1`0,1`?_$`,L```("`@,!`0``````
M``````@)``H!!P(%!@,$`0`!!`,!`0`````````````'``4&"`$#!`()$```
M!@$#`@,&``<*#@,````!`@,$!08'`!$($@DA$Q0Q02(5%@KP46$R(Q<Y<9'!
M4F(S)'5W&(&QT4*R4V,T5"4FMK<91X>X$0`!`@4#`@,$!`<.`PD````!`@,`
M$00%!B$2!S%!42(387$4"(&1,B.A0E)RLQ46\+'!X6*"DK(S<R0T%S?1=!CQ
MHD-38Y-4M#;_V@`,`P$``A$#$0`_`+^^X:P2!UA1.H-]M_P#2W#K/K"B;A^`
M#I3$*,[_`(;#I3$*,"(![?X=*8A'03B;AI3$*)U!^/2)`ZPAKJ.D8Z@_`!_R
M:14!UTA>'MCEK,*,`8!]@^_;2G&`0>D9THS&`$!]FE"B"(![=8)`ZPH$_D)S
M$Q-Q[ZHJ9<N+1=SH$7;TJO'0/((D4#J16G'JQO203=8H[D\WJ6.&PD2,4=]"
M7D/F;#^.R:6N<-3?"B8IFB"L#L5DG:V">DYJ/9)B*9#F%HQX;*@ERLEHVCJ)
M]-QZ)G[=?9`BLN6_-G)Z?S/$_&UHQKJP]3.0F8^8>`X2/XD4))2LC6&#HO3M
MXHI"7\NA!3\O<X98#4XCC:&[:=4K=0Y,CPWN*;0H^X"(@WEF;W.:[7;$I8.H
M*PKI[U%*3]`UC[..5O.'&R8RF4N-365KJ`@=\]@X^6:'01*&ZAS/XB3M#1J`
M%\>I9`"AM[=;'N6><L9`JLIQI#ML2)K4TAR8`ZDK0MQ"?>4RCTO*LWM(]6[V
MU*Z4":E(W"0_.25I'TB-[T3N&<?;94)6QS\N]HDK!-@7D:E.-Q=RSLYS>6FE
M6U&!5$;"8ZNQ>D@)*IB.ZA"$W,$[L/S$<>W:T/W*X/KH*VG2-[#HW.$GLR4_
MVVNF@!'50`A]MW(6.UM&JI><+#S8\S9U4?';(>;Z->Y`C0Z_/_,.3I-U$\;N
M/DG9&C90R(3,ZC)2Q]@,($6=M84S**B3&+L/0L_4$OO_`"0%WYA<RRFK72\:
M8^Y5,CHZX%N&7BH-;4-G^2I:O:1#`>0+K<WRQC5N4XV/QC-7NF$R"?I48_0.
M=^X]#%^92G'BORK%,/-48LH9=5UY90W,4$XNXO'W7M[.E,X[^X=;59Y\R5"D
MU55CU.ZSU*4MJ49>YMXK_`8VJOW([`]5VW-J;\`)GZDKW?@C\O\`[/EHF.=0
M]IP39HW)C9=)FE7"R9FL>X74ZB]:Y9"*)/LC`?I`J`-5S*;^!PUSCYI/A*=5
M%=+!4M9.DA/H[RE)/0F2D>H`/#:J?3<(UCE`,MEFMH7D7-)EL!`23WU4-P]V
MTS\1'JJ?R#YSWYP$DTX_QM8KJW2HT&2AI1NY50,.X&\R=GHQPMN7_.*W(4?<
M&G:R<A\\9"KXEG'VJ:W*U25(4DD=O[5P$Z=P(ZJ+(<ZN!]1-N0U3]1N"ID?S
ME#\`@PJ-?,EKB@VR%2TX==7I*9PU0<-TA,(@'YXN'[8P@(^P%`T9K)D&4+4E
MK(*(,N&6J0?I[D?5$PH*^YJ4$U['ID]Q/_B9QOH#`(`/CX@`_OAJ?`C0^,/\
M<M>H432A1-]8*@.L*)I3TGVA1-_PV'2F.L*$_P#=2[M%#[;D'3ZTPIBV6\^9
M-9NY"D8Z2D5(>(C()HY^7&MEOE$&CUZG&N9<1:LF;1%1W(+IJE**14S*`5^+
M>**_D6I=>4^*.PTI'JOJ&XDD3V)F0)A.I),D@@R,Y0+N1N2Z/`V&64M&JO=2
M#Z;8,@`#+<J6LB9A(&JB#J`(5D'=C[YM98,,DW'M@LWN,I(6+M-C'8ZRM'2R
M$=(*)`V,LY0M5BFX<%B+%V</8@");@=0G2`AHH?Z6<(O.O4%+DZQ<&Q(%3C&
MPJ'@=B4KUTDA4^TX'7^I/+C*4UU38`;>L@@!E^<C_.)29=U:#PA[G-?E!FWC
M#Q=C\V8TXW3N>\I*RU"B9/#%3<V"1?,1M"?_`%$Y0>5JL6"4>-*NN!B&5!B4
MBA=C&\L!T#,-QJSY+DYL]SN+=!;0EQ0?<V@>3[)(4H2*O#<?I@QY9D-VL..)
MN]OH5U=R46P6$[B1O!*AY4DG;TG+J=90B6__`'#',_$\`-LREVL+KC>K`^:Q
MHV2]6#)-4@@DGP*"R8#*SF(6+('KOR3^6EU]9^@=@'8='2W<`8C=ZD4=JRBE
MJ:L@G8T&W%2$IJVI=)VB8UE`8K^<<NMC!JKACKS%+N`W.!YM,S/:)J;`F9'2
M?:.TJO?\YU7RNQ-OI':9R3<:G/M?6P5GJ\EE.=@)ED*JB/JXJ8C,.N6#]KYJ
M1R]:2AB]11#?<-:ZS@;":"H715V64;58A02I"_22I/0G<"],&1&A$;:;FK-*
MQA-528V^Y3K$TK2'E)5*?0AN1$QV,/*@.:C*J<"X[FUR;H,[@E./QD:_Y"QB
M\;R3JT5:1,_5C&-.:LYN.K\FZGIB0,V;M$W#=J)EW1`-T%W-H&N8@NKS=6&X
M\^W6DU19:=3+8X!_XDTE0V@3)E/0=S!E:RD4V'#*KZRNE(I_5<:U"DJG((`6
M`05&4IRZQ7H0^YAY$WE],2.'NWC)VZF-))9FR?-K)?K4_;)@`*-T9UW3L=/(
M=I*G;'*=1!,Y@)U>!C!L8;$?]->/V]"&+WD"6JTC4!+:!.6L@M>Z0Z3Z'M`)
M'/\`?JUU:[390[1A9"3O6I1\`2$@;I:GI!H\".\URCY;\IL>8$R3P8F<+T^X
MLK@YDLBNR9,]/"*5NIR]A9)&&Q42%B`^:/(XC8/-<)CNK\/4;8HPS/N'<6Q/
M%ZB_6N]"KK&5-!+4VCOWN)0K1!)T29_08EN%<JY)D^1,66X6H4M*Z%[ES7-.
MUM2QUD-2G;](AW_)G.$5QMX]9HSY,L/FS#$6-K9?#0XNPC_G;JOQ#E['097X
MHN`9GFI%-)J57RU/+%4#=)MMA"6.6=S(K]1V)E6QRKJFV=Q$]N]0252[R!G+
M2<H,.07=%AL57>G$E:*6G6YM!D5%*20D'M,R$_;"L.T#W>W?<J?9?IMYQE7<
M4Y&Q>SK]HCXVM6*0GHNSTJ?<OHU=\D669-'K-_7)9LB@Y^)1-4'J1B@3Q+HH
M\O<1(XV^$J:&H756ZH*D$J`2M#B`#([?*4J!FGOH>L#?B_E$Y^JII:NG13UK
M$E`))(4@DB8F9S!E/M(B&6\PN2=;XA\9\Q<CK2R^;1V+*@ZG&D#ZTD>I9+`X
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M3;OCH&6?3CA`=P6;0;,!4`H[E.N9(@^!AU4+F7D/_3W$EUM')5ZJE>C3CL%D
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M7<A7ANC4N4D(4VA*3UV^H]]LR[(0):RF-8+Z*%"$A50K:)?1'6UOO_\`,[CK
M<X.![B'!B6H=4FW)4/J*K52\XXLC=$P@+AW#Q.07<M6;@+)+<YFJ$FT5,`#\
M>^P:W/<#8?D%$Z]@%];JJYL:H6IIQ!TT"E-24@$Z;BE0]D)5$RX/\.N:O"'>
MPN!>)'.*#Q9REQDZ,YHEW9DLJBU98N*VQR'&F,NB+2PQCENQ?0TLQE6YDGBJ
M::;A3RU$SF'<JA?G_P`A_+GBE?F*7[Y2_!W>C?(JFV=J45.T3"5[=!J0K>B1
M4)A1UG`]O&!V.Z7%-;4-E#J#YTH.U+OL6`/K(D3T,!1S=[VO&K@M8C\:>/>,
MCYWS-7'!*\\H=`.E7Z!1IP_2FC7)B9C8V5>S=M!02@M&13-TN10W0X626W)J
MVO&'R^UMUL[=9_A[-B2$S1Y$H*D#4K0CRI"2`9.+4)]9*&L36@M33%.EIA*&
M:5(T2``![@!`3%[V7=KKAHRUWCM:2A<?R3YB@B#/'V>H"0<$D'"3=BV0L$@R
MF6;1R\56(0BKB/*D)C`.P!HD+X9XI>2IBBRELUR4DR+E,L"0))VI(49`$R!F
M>T=AI*8C1SSB+0E0BD[A#T'(M^QG!U+)ZE6BWLA%NSQ5GFZ#*S$>U=S57:6Y
M*/;"^&)>&,W.NW*FDJ9,3%#I$-ZHW*QV,WHUS;;%344ZU(9J2TE+A0"1-).Y
M:`KKMW:3\89G:.E54)J%MH6^B>U9`W"?@93'UPI;MU]U^X\W^6G)/C=8,-5J
M@1>!X^W/8ZTQ%ME)V0L1JWDY&@HIO8U[$,&[`';93U)A(JITG#H#</'1PY"X
MKI,*Q6W9"Q5N/O5JD`H*0`C>TIPR(U,B`![##D_3)9:2M).L.TZ0'P$-P]X#
MX@/^`?#07D3UCDT,`7W*.8DWP1XI6OD97J/%9$DZW9*3`I5:9F7<"P=)VNPM
M(19P>18LI!PDHR3<BH0H)"!Q#81#VZFW'N),9ME3&.U#RF&7D.'<D`D;$*7W
M\=LHWT[7K.>G.4X]9V_^44MS/XDXEY)3E1CJ)*9(:61PZJL5*.9IA%#!6^>K
M*96\F\:,7#D'"4,541,D7I,H)0W`-QYLYQMK$,KK,<9=4\U2N!(6H`%4T)5J
M!^=*,/M!EPM@SE!E:B<:83QW3>[=2NW6WI]#KU&6S#R%R3'JRM3Q^206BX:$
M@/7'B6MDMCYFT?2:J4I,)G:Q\>R1,Z?*I*_&B4@&,6.,.*:[D)U^MJ'OA,?I
MC)QXB9)EN*4#03"=2I1DD$3!G(=5-3E\S.C8ZF%HH]UCOAU,D3>;_P!L5F[Q
MS+NXS9I&4/*,5*-F4LY01:^I?-[/:92"Z_4%_3R$24B6_4H0`WT0U<8<*O\`
MJ4M%DROCVTJ^TID@D`F29(2%]/Q%GPZQT_#49&CFL6F?53?T_P"M^5MOJ+Y/
MZKY)\P_HGSGT/G?*_FOI_P#=O7_H?4>5^;\?1[M5EDSZ_I[Q\-OENEKMW2WR
MZSEK+QAND-W72*F'W#'$OD-&<@,%]PS#%2DLC5C%$'3X^YQD?$NK-]`SN-+N
M]NU8LD]769#.W-$G#2/D/ED]R-E6_P"F,F58APM9\OV5XZ[C]QX\O;WP[U<X
MLMJW!`<#C8:6A*YB3HE-([SD-08K!SEC5[:O=%G-J:+S-*A"5ID5["VXI:5*
M2`?NS.1/0$&9U$&OPB^XBXE\DWM6H&<6;[C1EJ<691!%;$[3EL1SE@<"FV(W
MBKXEY2M="0>FV11F6S4B8F*F+E0VQC0[-OE[RK&T.W&RJ1<[2W-7W>CZ43U)
M;_&D)3*"9_D@1+,/YTQK(5MT-W2J@N:I#S&;))'9>A2">FX2_E'K%@Y,2G`#
M%,`@)0,42#N42F^(IBB`[&*(>S\>@")&8_&'7L?I@X`D]]#^[ZO"$!?<J[AV
MUEMQ]N?<1@.WX@"S#[_W-6`^6O3DH'K_`(!_]]N`GS\=N`*(_P#EM2_HN09G
M9IW-VON&8[__`!,0/?[/J6P`'[VH5S%N/)EW)^U\2)_^VB)7Q3IQ[;)?^0K]
M(N-5]^[P[5O)G_ZO_P#+5(]FG;@<'_4^W'IJYT_NU=(;.:-..Z[V^E^D3"9^
MT_WJN#?"WA!C+`66D\J-,C5R:R!+6@U.QLA,0[M>RW>;F(QT$L2;8GD70P;I
MJF<YTP,04P3W$I"Z,O+/"F<9EFU3D-H^&-M=0TE'J/$*&QM*2"-AD"H$B1]L
M";C'ES#\3P^GLER%1\<VMPKV-I(.YQ2AKO!,DE(.DY"7:+('!_N"\?\`N#5&
M\73CZ>[GA<>V5C5+"-WK!:N[^:R$4G,MO0-PD9+U3;T:@=1^HNQ_#;WZK=F_
M'^0<?UK-OR`-"H?:]1/IJ*AM"BG6:1K,?QQ8#$,VLV;4CM;9?5]%EP(5O2$F
M9$]`%*TE[9P&_P!P/DP<<]K_`#6Q25!-UD^P8XQ>V$#=)A)-V^.FI-,OB'5Y
MD'7'0&#^()M3#@2V"Y\G4)*9M4Z77E>S:VI*3]"U(B*\V7$T''E6$&3CZVVT
M^V:PI0_H(5%8/MX)6SML<Y>W?EFVR:B6,^;6%X-29=N"G;,F,!EZ=D:I\M=F
M()4U!JMJC8&5$QMQ*W<D,(;#XV<Y#=I.2\'R"UT:9W"RU:BG74J82%D@RUWH
M4XF7Y0`BN>!MO\?9A9+C4*E;[M3)W$C\5Y11+KIM4$+)[)]\.2^Y9S7.3-2X
MO\%<?'.^NO(+)<7:YJ&;"H+AY&1$LVJ6/XQ8I!W.VG+Y/"L4!`?CB@$/9H._
M+79F::MN6=7$!-#;J92=WA,%QP@>*4(D#_*([P5^?[J^_36_#Z$SJZU\*4G\
MJ1V-I/AN4HD#Q`\($[L25A_Q%[LG,/AS,2QY(S#']NJZ;]4OIPG)/%ERK4A%
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ME:"-$23V0;EZ4A9NW660`@.7[R0>BH*)#F$C1N)$$@*F0H:`>899=LSO;MYN
MCBEE2CZ:"3M:;GY4($Y)`$IRZG4ZQPO.K>65J,;EROA[%V=*5)8YS%0JMDFC
M2RK1>0J]OB&LS$.'#!P1VR<>F=$,"3ELX3`Q%""4Y?$-]A$!9;9<[G9:Q-?:
M7W*:L1/:MM12H`B1$QV(/2/"5J09I,C`[\ZLM*\4>#7(?*F/X]C!OL5X;GOH
M1C$,VT='0$LJR3KE3/'L&B231HTA9.1;J)HD(5,I4@*``&G_``JTG*<TH+77
M%3B:FK3ZA425*2#O<))U)4D*U,>VD^J\$J/4Q3L[-W+_`+=/#8;OG7E8]OUK
MY4V:RR3:NRR6-Y&\-:34E"(.GTW$S0N#)A=+Q-NG2LB\`/4IMTTTBG`%%O,M
M[R_A_(&7?#V+%_AVL48:!*2[Z9<5J`E:`G[+:0`D3(,^DP).U4S4NGTFY>EX
M1:RX=]VGB!SHR?+8BP'+Y!?W&%ILA>WR5IH4E6(XL!&2L/#.CI2#M=5-1V#V
M=;@5(`W,43#["CJK>8<5Y9@]N;N=]2PFF==],;'-QW2GJ)"6@AL<IGF4[EC2
M&8[>.^AS+S3C1.*<?8'_`&I/<._J'*7_`.C6NK?\]?[:6#^\9_\`K+ATKO\`
M+-_N[1<=U4&&J$@?<.?LP\H?VA8>_P"_8K1CX%_W-HO[M_\`0KCMH/\`,B-G
M]BO]EGQ;_JS(7_E:\:;>:?\`<^[_`-^G]$W'FM_S"H;AH71R143[^7&'D70>
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MR$8N0&WJ0<F`G4"?0(&U)+?B647:UKO%JH:FIH&WO34MI!7)82%2*4`JT202
MK;+64YQ':W*<<M5P3:+E6,4U<IH.!#J@@;"HIGN5)$RI)`3NGI,"454/N,J]
MVZ3T7']YPS*8<#E?-WM%.?1PU)5IX-CQFI"RZD_,9,95!9>)3=LY9)B$>]=%
M3?+F54(4RJ0&\NU7RZ5'(:+C46^](J_V4;IR4_%)6`V\"D(#)<DJ11O*DIFD
M2$Y=ZW<[,8*NAIZZSJICDRGA_ER@[FY&:G0V2F85L"5'S&9Z@:66NV2&1P[?
MW$+];/S;Z]_431?G'SX5AFO2C&E&O_-!<"+CUOTT+/S/,'S.K\[XM]5KY(-N
M.?7;]4D&@^-<E(2&Z?GD/#?N]DNFD6!X_P#C?V,MGZQW?&?!HGNU.V7DF?S-
MO\,+F^Y7_9K+?V_8D_T;-HE?+9_N2/\`D'_WVX@?/_\`^`5_S;?]5R#,[,_[
M+WAE_9,3_N6P:A?,7^YEW_YD?HT1*^*?]O;9_<J_2KC67?H;.'/:NY/`W067
M].WQJ[7\E(ZHHM6^5Z0HNX4`@")44"!U',/@4OB/AIQX+=;;Y0MH<4$A2G$Z
M^):5I[X;^9D+<X\KPA))'IG3V.)U]P[PICL[Q/:#M7!;')>3T=PR5SM"6'($
M9>U,V$Q[%WQ0%+G-/ZTJZ5N"C5_)QXU=VT*V72%1`$R@F`@8AR@4N8U\L,9W
M4JQHWC]2N-M%OX;URU(-@+(].:0?4"B9R)ZRU$#'BEOC![#*<9$+5^N$+=#G
MKEH.:N$IU7(D;"F4IRZ3ZP_CBY;^W#1I-UBSA[<>*$%-7I\K-NJ%@ZU8[)*6
MB0AXLXKR9H"K2*CN2<1T.V,)U`3,*2"8B(@4!V`F2T7(%:V+KEK%U<99`2':
ME#TD`JT&]P2`*CTGU,&W':K!:-?ZMQAZVH==5,MTZVYJ*1UVH))(2.L)"^Z;
MOSH,+\4<(Q+D3R60,M6BWK1:9_C=%I]90KD/UI!XF(I+WO8@^.QB"'OT;?E?
MH4B^76]JG*FHTH'@?445&9[?V0/TP(_F*K)VJV6E)^\=JBN7L2`D?UU1Z#OK
M\+U&G;!XWW6HQZC6U<'8S&L0Y7CT"INV=%EZW6Z/9W(*I]*R8Q5JC8A^(AX$
M\I0_@.^_/P9F;9Y,N-%5G_!7M;Q`.OWN]3J/9]E2Q[3(1LYAQ(CCNWU3"955
MI2RDD#784);5J-1YP@^P$F`/[;ELN?=B[O-$Y.Y-B%B5OB]A''\^^8.5O6,D
MK;2*JQJ==424_FT5;%EB6D[.DGMU%*W$H[B01U/>2:*BXGXE>QBVN!55=*YU
M,Q.?IJ<*U#^:T$-Z]9F(3Q_557)O);.1UZ94UOI6U$=05MH2D'7\ITJ<!ZQO
M;-&_&K[G?$UL+_RR$Y`MJ.14W\T@^-DW&,UB98IMMBG%>Z5I,PA_K.DP^.H_
M:#^TGRRUE.]]NVN*D!K_`&3J7?ZKIA^NH-@^8.F?2K:W7)05>YQLM2^E:(<K
MSY]1C7D1QMSHH@8T+%/&$=(JD*/Z,]9L99A=,Q_$"F7AY=<2![_*-^+7R)^8
M$.8UR+C.>%"C2LN)0LCHDMN;IS[^1Q9EX""-GT[;D5MOY'W2%;23TFE4Y?T2
MI7\W2%Q_<D\:KA><8X&YKXK2<3`8#=N(ZY.XE,STT52[1(PMAJ5\("!3":(K
M]ICB$<J?FIIR!%!V(0Y@^I_RW9;:DU-7C-8XGX2ZLI6RJ?E6=I!0.TW&US2>
M^V0U(@V6Q]#@*0?NUIF#V,QH8:WVZ>YS@7G?B*KR<?<:W6,Y1T-',\H8AF)=
ME&V6*LR#8B,E)UY@\406L-1EG29EV;MH"I4TE2I+>6L4Q-#CD3C>^X)>'F7V
M7%V0N$LOI22V4$S2E1UV+`T*52)(F)B-+],XRHS!VSZB-]\J.=?%SAE436[/
MN5H"LE57;-8NK1SA.?OL^NX632$(*F12B\[((M"*>:NL"1444BB)S@/2`L&,
MX9DV7U?PEBI5O$`E2Y%+:9?E.&21/L)S/81J;9<<T0#'2YZK./.X-P9RK4\3
M7>OW*E<A</6./Q_=H-\1W`O9-VS65K;TSCI`Z";&SL42.TU"D7;F2434(50A
MBA[LM5<<#S6FJKFTXS5V^K1ZK9T7M!DM(['<@D`Z@@S!D1'I!+#H*AJ#%1WM
M#.NW]7[CD;AEW)^.^(J[G""R%*-J?D7,L$DR,:73%M%3N)[;/2*S=G"/8J38
MF=0Z[@4VKU!V=,JG4"(*VRY:&>5%%39IQU7U3EC=IT[V6#NDG50=0`"53!DN
M4RDIU$IR<ZD/%(>8)V>`BVSB+BYP$XI3*F6,.XRP'A27FX?Z44O4"X@:[\SA
M9F1C7!84DNO)$:N6\E*,FHD3*8145(0"[CL&JI7;)\XREH6V[5%;6MMK*PVH
M%6U029JV@:$)G,]A,F&Q2WUC:O<0(-SJ]GNW'4,"Y^_^.1^HQJ(BD;V;,YXA
MX[]TSG6&=<AU7$B%L_7)6(.0R!+-:O$N;%%9Z3F74(M+2JC:/8R(QC959--=
M1/S02,!-S``#=+F*T7/(.,K&JQLKJPWZ"R&DE:@@TZD[MHF2-QEH#X](=ZM"
MG*9O8"?^R+8`\]N$)0$QN7G&LI2AN81S5CP````1$1$;!X``!JJQPG,TGS6F
MXCWTSW3^A#6671U2?JA>'W`:J=A[6&39F"43F(E2VX6G4I*-4*\8JPCJ]P1F
MTLDZ;BHBI'KD>)&(J`B0Q5"B`["&I]P2E37*%&VZ-KB45`(.A!#*Y@SZ$2.G
M6>D=%#(5(G&MNRES1XE4?MQ8&H%ZY&X;HEWI(WR'M%4N^0*U49Z*>N<AVF9:
M>9&V"0CW*S5Y%2B"Z*Z13HJ$4V`W4!@!QYCP_*JGD6XU]);ZMZB?<0M#C32W
M$*3Z:1]I"2)@I((.HEJ(]UC3BGR4I)$.+H/+#C#E6S-*7C+D+A;(5P?MWKMC
M5J9DRGV6P/&L<W,ZD'#:(B)=V_619-BBHJ8I!!,@")M@T([AC>1VJG-5<Z"L
MIZ8$`K<9<0F9Z#<I($SV$]8XU-.(&Y23*.MO7+WB]C7*S?!>2\Z8SQ_E*0JS
M&X,ZA>;/'5=>0K<J^DHMF\:/IY1C#NSN'D4N3TQ'!G(%*!A3`ABF';0XEDUR
MMGZ[MU#5/VSU2WZC2"OS@!13)$U"0(,R)3[QZ2RXI&]`)2(J?_<4USMZ)P>,
M[C@E_B!/D_.W)P2[,\,2-==-IW&QH225D)S(K&H++0S>:;3R;(L>Z7*G(.06
M6`153+NG:?Y>W\_34U5%D":H8XVR-AJDK&UT;9!HN`$IVS"D_8$NW=RH2].3
MD_1]O\</2VY%?^C[VV'^\5_<$WW_`*7]8?.?U5[^W?U_U;\A\/\`B/7?R]`J
M>._ZSRFS^SGZ\G_Z?I^OUG^1^"6G2.+R_%?R-\>SYO\`9XX:\^;LAD_,D5D&
M%R:W@(ZL?6U`N[J'>.8.(4=K14<]A)EI8:JJBR4?+"4Q&"2QO,'J4'PVQA/+
MN8X%1FVV5;"[:5E?I.MA0W&4U;DE#A)D)S61IH!`OR[BW%LSJQ<;HE]%P"`C
MU&G-IVCH-J@M`EK*20==28'_`(\_;R]NS`ERA[X]K>0,TSE??H2D,PS!:6$Q
M46<BT4*LS=KU"N0-9AIHS98H'*G(D>-Q,4!%/PT^W_Y@.0[_`$"K<'*>CIU@
MA1IVRA:@K0C>M:U)F#*:-I]L,UDX0P>RUJ:]:'ZM]!!2'UA2`1WVI2C=[E[D
M^R'E)I)I%*FD4J:9"%3(F0I2$3(0.DA"$*`%*0I0V``\`#03UZG57C!>`"1)
M(D($'G#PKQ?SWP@;`N7IJZ0-0/;Z[=!?T.1BXN>^:5D'P,4/4R\/.-/1*A('
M\TOD=0[!L8OOEV$YI=<#O?Z]LZ&%U?HK;DZ"I,ERGHE23/RZ&?T1&,NQ.W9I
M:/U-=%NHIO42N;9`5-(('VDJ$O,>T;-XR\?Z?Q7P-C+CUC^0L$K3<5UX*U7Y
M"TNF;VP.V(/GC_S95U'L(QDNY\YZ<-TVZ1>D`#;WZ;,CO];E%\J;_<$MIK*E
M>Y00"$3D$^4$J($AW)APL%DI<<L[%DHE+52TZ2E)605$%149D`#J3T`TC95Y
MHU0R93[-C^_UV+MM*N<)(UNTUF;:IO8F;A)5LHTD(Y\V4#91%P@J(;@(&*.Q
MBB!@`0;:*LJ[=6-7"@<6U6L+"T+29%*DZ@CW>V.^LHZ6X4KE%6MI=I'4%*TJ
M$PI)Z@P@>P_;*=NZ9FI"3C+!R)J[%XZ5<-:]$Y%KKV+B$E3F.#&/<6&BS,TH
MR0WZ4_4NW*H%#XE##XZ/5/\`,OR,PPEEQ-O=4D`%2F5[E2[JVNI3,]3)*1/M
M+2`J_P#+[@SKRW&W*YM*S/:EQ&U/L$VB=.@F3IUGUC?7$3L2\/\`A;GZF<C<
M56W.,I>*,VLC6(8W*UU23KJJ=HKLC69`7K*,H\,\5.G'R:ADNAP0"J@41`P!
ML+!EW.689I8'L=NS5$*)]2"HMMK2OR+2L2)=4`)I$_+TTA[QCAW&<3O+5\MS
MU8NJ:W;0XM!3YDJ09@-I/11EKU@B>9/:_P"/_.3+V$LQYDL64&LS@<S<U1KU
M2GX*-JL@*5JC;:X^H&,E69AZ\^8O(AN@OY+AOU-B`4-C?'J.8AR7D&%6FML]
MF13>C7@AQ:T*4XGRE(V*"T@2!)$P9'7V0^93QY8\ON=+=;JM_P!:DEL2A20D
M^;<=P4A1UZ&1&DO"#7S!BFG9SQ5D/#F06)Y*DY.I\_2;.T2,FFX-$V*.7CG2
MS)55)=-O(-"K^:V5$A_*7(0^P].VH=:KG5V2YT]WH#MK:9Y#J#VW(4%"?28)
M&HGJ-(EETMM+>+<_:ZT$TE0TIM8'7:L2)'@1U![&`[X!=L_CSVY8/(L1@UY>
MYQSE"4@I&SV#(LO#3D\9&MLG3.(B&3J&KU>1;Q+8\@Y7%,4CF,NN8PFVZ0++
M\]Y)R/D:H8J+]Z*54Z%!(:2I"?.05*(*U35H-1*(OAF`6/!FGVK.75"H4DJ+
MA23Y9R`*4ITU/6?X(ZWE+VP<`\M.2&#^4U\L64*UE+`?TP%-6HD_!Q,.^"H7
M52]PH6%G)UJ9=/?)F%U2&\I=#J;JF)X#L8,XQR7?\5QZNQF@13.6RX3]0.H4
MI0W(],E!"T@3$NH5J!X1XR/CRQY-?*7(*Y3Z+A1E!06U)2#Z:_42%32HD3ZR
M(F-(*CD9A&'S_BZ;H$DJFR?JB65K$R=/S!A;(P(H,<\,`!UF:+`J=!P4/$S=
M4X!X[#H!<CX-1<@XN_C]40AXD+9<E/TW4:I5^:?LJ'=),/V161B_VIRWO2"S
MJA1$]JQT/TZ@^PF%Q8$Y*KX2+)\5>7L`+2#CVSJNQDQ/QWSR%-6I!-1J:!L3
M99!TWGJ6^:JF(T>%(LB#8XHK%\LH=%=N,.7[GQG5IX\Y.#U%44:@FGJB%$(`
M/D!4F9+8D"TZF9"="-)P/<;RNHQMW]F\I2II3.B'>HVG[(TF2GP4.@T/2`RS
MO]NCPWS].KY.XL9IGL$)3"QY+Y%42Q&3,:MUW1A4,:KMSR\7/U9N<QA'TZ4F
MJV2_-212*`%#Z?85\T-W7:DHJ11WNAV`)=#@W$=1O4D+2HRTU0E6GFF9P:*.
M\-U#06TM#K/Y22"/P3CSF(_ML^+>+)Y'(G*SD9<<S0T.J1XYK\@E'8JI\B1L
M<%?36B<4GIVT2,8?;XT6\@P$P")1,8!VUU93\T=UIK4LT#%%9V1/>^M:52$N
MJ?42A`([3"O8F>L>JF[ML-%:REIH=5*(`_#("&/S_/W"F$7M(Q5@+'T1(XDI
M"3:%EC59BE6Z]"UUL3T;:-Q]&(I-6B_HU1*<5EBIMG`@)""8RGFE^<&:?-19
MFLD2+6V[=J93RE5=45*!/FDKTMVJU`R\RI(5T2>\">[<G4%+7I8H4&HI@?O7
M`9#W-]B??('H(\?R6X"=NGNL,D;V_<)0^6!CD&8Y(QK)Q]4RBD@BETM8V\5R
M49/65F18AL1/YDQ7533+T-W!$]M6UX@^9!=/1)7A%R8J[:OSFE=/F1.6[[LE
M+K2NQEY.Y"C*)_9<GMMS;#MM?;=2?Q"9*'O29$'Z)>^%X1OVN.'4)5!2T<QL
MRRU.8KE<)P3"FU."D6Z*)^LGDS[R4G(]DLB!0V63C2"00ZB@40#5@ZGYG+I\
M.KT;10MU!29K6XI23[5)"4$CQ!7KW,2`W&0GL3]</X@L]<>L0IT7!TCG!M-S
M=>KL15T9RV6`E@F'HP,>TC&[N\W-HU1A2V:4*@!USKF0.NN)S"4HCXTHO/+O
M'R,B-OK;G0LW&H<6K8VK[ELDSV%8*D($S)*5*T&AB'U.5X_3U@HWJMD/K\%3
M`]A4)I2?>8!?E5V0^!G-+),GG.PL[O2[M;SIO;;.8<N$5$PMXD02*G\^F8F1
M@[+#*3:Z1"`L[:$;'<B'6MYAQ$^K)X=SGF.,V9JVVMZEJ[2E/W7JI]4(0==J
M%H6DE'A,F70$#2)-37%7IA3*D+:(T(,Q]!&D"J[^V3[>B:9DG60N1Z`+E,F`
M'O\`12'.!RB003*;&^YC;#X;`.I5_P!3F>,*FMNUA9&DVE@GZ/6$Y?PQM5<W
M`=IV3/[O&'Q2>#\:V;"0<?+I7&EYQ6YQ_'XTEZY:$R/49ZK1\,UA4D)042-=
MW9VS,BGG(@BHDN4%$A3.4H@$47BX-7G]H*1PLW/UR\%HT*5J45';UTF>FNFA
MGK'(%J"]X.LYPCV;^V;[>DI*/7[&R<BX)FY746;PS+(E<>L8Q(YA,5FS<S5$
MDY91LCOTD%PY75Z0^(YA\=&MGYD.0&6DM+;MSA`^TIE<R>ZCM=2)GO(`>R.P
M7!\?D_5_'!%\.^Q]Q(X29YKG(C$MIS5*7BL0UG@X]G=+35Y2OJ-+9$+0LD=R
MSC*7"O#KIM%A%(2N"@4^PB!@\-1O,>:<NS>QKQ^\(I$T"W4+^[0M*@ILDB1+
MBA(SUTU]D>':QUY'IJE(^$>^YK]G'AGSNOJF5\N1>0X')ZT-%P#NY4"\.HI=
M_%0B2B,0T>P4XSL=7$C%-4P%,BR05-N(F.(B(ZXL+Y<S#!:$VVSKIU6\K*_3
M=;W!*E2W$%)2KS2`,U$2&@$>6:IUE.Q,MOMC3G''[?[MZ<>;I#Y!-5KSF2R5
MY^VE8)+,5E83U7C91DH59E(?2$%!5R!EG#58@'($BD]2*<H&`@"`#IVR#GCD
M#(*%5N]9JCIU@A1IT%"U!74;U*6I([>3:9:$F/:ZY]2=DP![(=MT%VZ=@Z=N
MGIV#;;;;;;;;;;W>S0;VB>[\;QCC_P",<M9A1-*%[HFE"C`[>_2,N\*,ZP)=
MND*)K,*)I0HFE"B:4*)I0HFL2A1-9A1Q$"^_;\GC^_K$O?"@=N058XVVZ)8P
MN?Y#'D61P5?Y`^MMGAZE-MS[=*RM?EWLA'/R"0Q@$Y4SF2,(!UE'PT.N0;9Q
MI=J5%%R`Y;F@H'TE5#S3#@\2TXI2%^\))'B(CN0TN-5;"6<A53H29["XM+:@
M>^U1(/OE],+\1X9\9W\DNMB3F`E7C&.(^CB;]2;`LEOX]'J(6<A71]O8`G$P
M[:KH.%N+GWRYB&9(IA/[**JF>D/";;S9EX3F?;`\_8S%G%;K3>$M)/9+K2Y>
M[:M.D?5SPSXX,7K=;+_,$;`F0X#Z.9OU-KYE@`=P("\W.3+@@C^,FP_BUM'"
M_&C%0'<MS%-0V/Q%5=.R#^<5NN']Z$<,QELA5YO(=:\%.MH_K+5^"#2QI4^&
MM5H5G@:))87E*:1DD2^R![;5;0FX:GZ2)*W&;<R;[H2,KXI@NHFD0_BF4HZ.
M.,VGAJU6"IH+`Y97;,&P*E?KL/@ID=:APK5IUEN(`[`1.+;2X92VUQB@51*M
M^T>H?4;6DCMO45$>Z9`\(#ZV\4^#%HEQ?X_Y%57'LHY4,J@PKF6:/-1Z)CCN
M!8]F^ESRB"91]A".ND`\``-!J[<3\$W>K548SD=%;JI0)*6*^F<0)GL@N[@)
M]`%R':(A5XK@M4_ZEON+5/4'H$OMJ^I)5O\`^]'XWG"C&J;0I[=S9DW-=``$
M47MF@630R/CX`XD[@_8E)T_[(0VUQ+X1Q4-C]:9QNH!V4\RD$=Y*-20/?(QS
MJPFUR_Q=[4:8=1O0-/>7"/K!CTK#C/VYFM9<0+C,-&D9%R<BAK6XSI4$I]NH
MD40,#--K*HPJ*!S#N9,S0X#[Q'VZ=V.,_EL:H%T+MXM[E62-SZKG3AT$>&UP
M-Z^!0??WCN:QKCH4Y8-6P7>Z_BD!7U)5M^L1\J!Q#PS&R"KS%O+HSF-,8!&.
MBK559A,A`$VQ3.*_8F")O`=A$4O'6BQ\/X/352G<9S"=,==B7Z=T@3&FYM](
ME_-C718A96W"NVW<%KP2X@@?2E<C]4&WCS'-+JZJ0?K"+;)`G3\:\K&BH<P;
M>U--TZ<#N(>SK'1TQW'+%:EI/ZQ%74C\I:"3[@%&)Q;;;1TJM*CUE_G#^`F"
I(#;8-O9L&W[GNT2!TTZ1(HSI';WE.%$TM.W2%$UF%$UC3O"B:S"C_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g759111suppcov_pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g759111suppcov_pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,`#<`P$1``(1`0,1`?_$`,8```("`@(#`0``````
M``````@)``H&!P$%`@,$"P$``00#`0$`````````````!P`%!@@!`P0""1``
M``8!`P,!!P("!P,-`````0(#!`4&!P`1"!(3"2$Q(A05%A<*05%"(V&!,C-W
M&#DD1+:R8[,TU'6U5I9X&1HZ$0`!`@0$`P4$!`D("04````!`@,`$00%(3$2
M!D$3!U%A<2((@3(4%9&AP4*Q4F)R@K(C,W3PHD,T%A<W&-'ADE.S)&0U-G.3
M)74X_]H`#`,!``(1`Q$`/P"_QN&L3$*.-P_</7TTIB4^$(X9QSN&E,90HF^E
M,0HFX!I3`A1-](D#.$,1,91QN&LS`SA1-P_<-8F(4\)\(YUF%'&X?N&E.%QE
MQCG2A1-*<*)K!(`F<H4:IRSFG&N%(#ZBR+9F<&U4[A(]B`&=S4PN0`,+:(B&
MX'>OE`].H2E!-/<!.8H>NHKNS>VV=DT(K]QU2&&U8(1[SCA[&VQYE'V2'$B&
MF[7JV61CXFY.AM'`9J5W)`Q/X(7R_P#)/.VA^X9X8X^6^Z((JF(#YZ=\LH<H
M#L0YXVM14P#3J#^$[GJ#]=5X<]3%QO%06=C[>JJYK@M14"9=J&T*`]JY]T#\
M]2:BJ<+=EMSSZ>!)./L2D_ACT?\`R$9FJI@=Y*XL6>(ABB`N'S3ZDC>R3]3]
MV9KQV`B4/T.JF'](:\K]0V];1I=W+M2I9HY^9:2ZF0[@IH@^U0$8/4"]T<E7
M:U.H9/$%0D/TDR/TB"PQ)S1P+ER+>O&-K;U*1B(]63F(&[*-()^R8MB`9T\;
MN5')XV4:-]_>.V64,7^(I=%?:'6S86[Z9U]FK325+#1<<:J2&U(2)S4%3*%I
MEGI42,B)Q*[/O6PWEE3C3P9<;3-27-*5`#LQD?9.-`7SR68]82RM<Q+1K3EF
M3`YT47K9-6(B72@'$H&CT092,[(-QV]#@T3*;]!$/70^OWJ:V_3U?R_:-!57
M>JF9*2"VVHC`Z1I6X1/B4)$L9F(_<.I5M;?^%M+#M6Z3F,$GP]Y1'Z('?&&_
MY[^2K8@2#_B-821`>\=0C.[)+`D&XF$5E*VH0GN@/J*>VFH]=^I[2/B:C:#_
M`,'+,<\8>/+/TZ8YE;ZW,A/-<L[H9XGSC#QTG\$9E`>3W$"T1)J7.F7NH66,
M3W^G",FLP#]P&Q1;(2'<C@9*%-ZF^,2;@4OZB/H+E1>J39JJ-PWRBKZ6ZM)Q
M9D%A2IY!1*-/BM*8Z:?JA9BTKXYE]BJ0/<TZI]P,Q+],)CIZ]S_R5D.3VQYQ
MNL3V`$?<EGBLW)]P-]NH5(>"^7)B(>NQ5U-OWUS6SU`[HW%4J3MO;-0Y;YX.
M$N*F.TZ6PG+L48U4_4"Y7!TBVVQY3$_>))F.WRIE]9@O*%FNQSQT$+=C^0JS
ME;8!Z_CDBE,/M#M2+-L)MA_8PCHQ6+>]TKM*+Q;G*1P]I.?@0#$NH+W4U!":
MJG6TH^/V@01:9RJ$(<N_2<I3!N&P[&#<-P_?1&2H+2%CW2(D0,Q,91YZ]1F)
MI0HFL$@9PHFLPHFL3$I\(4"3S.YGX3X)85D\WYREWS:"1D&T!6ZY`M4Y&V7B
MUOT5UXZLUF-57:H+OEF[1595595)LV;HG554*4OK)]H;.O>][TFR6-(54J&I
M2EF3;:`1-2B)F6(E($DX`'*(QNO==IV;:57B\*(ITJTH0G%2U$$A(!EV8DD`
M#$F*\P?DGYLG"J7FE>-7),[A5%981N!;)<'W6S;*&(NN:PPN*G]/;*$*0W6`
M.%2)&]!.;;<3^?3C9Z:H%MK]RT;5XT3+8;3,*[`"^E1'>0G#AP@(GKY='@:N
MCL+Z[5^.7%2(!Q)4&M*?#''C#W8+G)&2_C])SY>8DN\3"CAB3S2&)%'<8[NJ
MT0P3>.&D6T?(`$:NYFF;8CAHH)2=2*Y!.0AMR@"G]EO(WR=CHJ65.BL%/SL0
MUJG(GM`2<Y3'82)&#(SNUMW9O]LE4[J6OAR]RI@K(&0G+[W`D`RX0F-;\H/#
M[5%1RZX6\D&K9$G<6<N9&I(-D4P';K575$B21`_<P@&C*/33?5&2+M;%$F0D
MI1F3E*69P@5K]0=J;25+M=:$I&,RG#MGAD.V/4T_*+PO(HBXCN&G(F1;E.9,
M7$?+TYZ@"A``3)]YJ=9+N%`0W+ON&X:]O>F7<#!*7[K;4+E.2BH$\,B/KCRU
MZAK.\G4U;:Q29RF"DX_1#J>"W.:I<W>.<CR094.U89K,3:KC6Y.&R.ZCB2#!
MO3&;%])6!TZ:=+-").V?"?J,/N%2.(CMH+[TV56;,W$-N.O,U504-J"FB2%%
MR>E(G]Z<%G:6[:?=5D5?DM.4S`6I)#A!*0A()5.0PD?I!A-^5/RB^*=.N\Y6
M\=8,RUE>K1#U9BQOR4S5J;&V46RAD59*#AY4[Z6&%74*(MUG)6ZJR8@<4B;[
M:,=K],>ZZNA;JKG6T=*\XD*Y<E.%(.041(!7:!,=AE`HN'J'VW2UBZ:BHZJH
M909<R:4!1XD)DK#LG(GB`8^[!WY+^&\XYJQ+A:,XN9.@9++61Z;CAA./K[3'
M;&(=W&>8P+>3=M6S,KATV8JO@4433$#F*40#UVUXOOINNUDLM7>%W2E<;I*9
MQTI#9&KEI*M`.O-4I##.-UHZ^VV[W:GM+5NJ4.U#Z&@2OW2XL(F1HX3!,68'
MSYK&,7D@]6*@SCFCAZ\7/Z$1;-$3KN%3#[`*FDF(C_0&JXMI+C@:1[Q(`]N4
M'Q:TM-J<6?*D$GP`F82QX^O-QA+R`<@;GQ\K.+[EC.>B(*=M5%F+3.P4JTR%
M!5N5;,90$F<8FBO!32;%ZD^*U$[L@M@4'O=28@)BW_T4OFP=OL7^JJ6JBG6I
M*74H!26EK&H#S$ZTF1&J2<988P)MD]7;+O:]NV6EIW67TI*FU+(/,2F4R0$C
M2J6.F:LCCA#E+59H6F5BR7"QO21M>JD#,66>D%?[IA#04>XDY1XIN(!T-F34
MYQ]?870AIJ=VMJ6Z-A)4^ZM*$IXE2B$I'B20(*U2^W24SE4\=++:%*4>Q*02
M3[`(4#XW_,]B/R.9AR5A^G8GNF,I2DU1:\UV3M4]!2R5SJK:?8P+IP#*+217
M@Y5NI*M5C-A,Z("2H_SNHNQBQU$Z.W?IW:*2\UU4S4-/N!M24!0*%ELKEB3J
M3($:O*9YIQ@7[#ZJVO?5TJ+724SC#K+96"I05J2%!.02G2KS`R\PSD<(:7F?
M*D#A?&UGR-81,HS@&0G:L$SE37EY=R8&T3$-C&_LJR#Y4A!,`#VR"8XAL4=5
MWWKNNW[)VU5;CN4U,TZ/*@>\XX<$(3WJ5(=PF>$$*\W5BS6UVY/XMMI)`XJ/
M!([R85?Q\P%/\MK)*<F>2D@N\IRSQT-9K)W2K",DF$:JIW$2G%1,T71X8R9D
MRE3,0[U4BAU#@`&%2JG3GIW=.L]X7U'ZCJ4]:ENJ334PGI<D9:4\4L)]V2<7
M2#,]HMVW8*K>-4=Q[B4M5&I1Y;?!0GE+@V,`!@5$'A`L<FOR$N*'&NP.,*\4
M,1ON0TU7W:\"9]2G+&DXH;2S,Q4%(^MR3*'F9>[*(+%.FHK'L`:G,7=-RJ`[
MZ^HNQ?35=7;0T_5JI;+9M`*&P@:PF0TE2$E"482'G7KPQ3!NHK2VPPEII*&6
M$B0`$@![/Y=L:)Q]^3/\JL<=!\J^%MXQC7)E8B9IVJS4C*/VD>IZ*NPI][JM
M/5GT4R#U'*V>`?IWZ2G'8-2VO]-:ZFD<.W[Q25KZ$XMK3)*@<)%2%NRG^4F7
M:1'0Y;0I!"%I4#P.,_P_@AK:W'WBESZH],Y"\8;U7F->M#]!68GJ<Q(,;)MD
ME2EGXJ8JR@-%:M?XGJZ3IK)(*$5]'"1@,4^OGGU>]+MLK[\&G6?DFX&GT\\(
M0.6ZT3-2DI3Y-93[CJ?*<B"(&6XNG5KNE2AZG_Y2I"O/RTIDH<<,`%=BA[1'
M4\E>;?`3Q)5:.JDZ0[O)<K$_,8O'-&8LK'EJSM13422G[9+/7#)M7X9VY1$H
M.9!TW1,/4#9%0"&*!]Z->G950Q\+L6WL,4:"`[5N"14HC'4Y(K6HYE*`0,`0
M!C$ML6V;?:V`Q;&4-I&:SBH]I*\R3]'A"N#_`)/AB*#8!X#Y,+C<#=0V8^11
M*?X3;<7?QHXX^F@-T^]T?&]'Z=W^+5E/\M)*>4F_T?QWXG+X]D^=/^;$A^7B
M7OC5V?R,6!<3M,0<P\5X:Y(VO`:]:D[C7(R\P%?RC`1+>[0C252.K'%L2$8\
M>LI!N\:"1VV2<*+$%%5)04TU!$I:C[UZ8[25N9;5YI;=<+G;WBE+Z$ZDJ4/>
MDHI3K`.!"TD`C"8Q,<K[#:*RI2]6T[+K[:IA12,^\X3]LX$["WE6H.5/(/D?
MQVP^%[77+%BY>_,ELAJSU>-5'Y,?M8UPX!A`,D$Y-HD_+(E*D4P_R^D>K1CK
M^D]38NGM+OA%0P+>\EK0PA!24APR`PDD`2X"'GX,,TJ7$$!&```D`.`$L,/"
M&TG235+T*D*H0?:4X`<O]93`(:&"DI7[X!EVB.8I!][$0.W+7D-$<2^.&6.1
M4U69*X0^):R6QO:O#/6<;)RZ`R4?&`T9/GY#M&R@&?@;J4`2[%$-/NV;`[N:
M_P!)M^G<2RY5.AL+4"0DD'&0C:T@N+#8PG&K/'SS<KOD!X]I<@:O0I['$6K=
MK32@K=CE8V9D@<58[$BS\7L4FFT%!W\<'03;J+TCOIUWULVIV)?U;>JGD5#R
M&D+UI!`DL3`D<9B/;[)87H)F8.#4/C3`#\__`")X(\=^,XR]Y=-+S]BMKQ[%
MX[QK52M%+5=)*/;D<2"J)WZ[=A#P$.1=(7L@X/VT.\0I2JJG(F:;;$Z?WWJ#
M=56ZT!*&FP"ZZN8;0DY3D"2HR.E(&,LP)F-S+*WE21],(V+^2+FQFV+?YCQK
MY+0PLN47C:W-['<0*K%#N8KM&QNL4(T]UNEL(&*N5$_Z'`/71G/IYLZG30,[
MEHS=DC%LH2)>(YY4/]F.SX!)PYB9Q96^[SC_`"]??KZ&L?>^SGW<^VW=COJW
MK^BOK'Z*[W?^5?4/^X]7<['Q/\73ZZKI\M3\\^2<YN7QG(YWW/?T<W*>B7FR
MG+A'!I&N4\)P@7\FKCCEW,'&C#>4,;PLW:JU@NY6^1R7!0#1Q(OHNOW"#C&+
M2]'CFI%'"T;6G4.9%VJ4AA:HO^Z;I2*J8I]]-.XK39]T5ENN3B&7JZG0ADJP
M!6A9/+!X*6#,3S(EG(17SU`V.YW+;]+<:%"G6:)Y2G4C@E20`LC,@$2)X3F<
M)QD?C-\Z/"&[X?PW@'*3]EQBR)3:;4\<MV=B:I,\/3[B!C&$"V>5NZLR?*(%
M&9.AWC-I@C#LJ',3O+?WAN3J3T+WM;KG5WJV)5<[6\ZMW4DS?2%$J.MO!2B`
M3B@*G*<DY1T;!ZQ;1K;=36.Y$6^Y,M);TD?L5%(`FE0F$@]BY2)/F5G%B]@G
M%J1S-.,(P-$*-$#1Y&!6YHU2/.D4S8696X"U,S.B)1)T?RQ((;>FJ^*YG-)=
MF'@3G/4/IQG/`P<T<M;8"-)9*1*4BDB6$I8$$?5E"\O+8R:)>-/FD<C5JF8N
M";;TF(@D4P#T-A`0$"`("`AHA])9_P!Y5E/_`%R,.W/C$)ZF)2-@W7`?U-?V
M0O?\9ELU<>.VP&5;-UC!R0R8'4J@D<VP5ZA^G48IAVW'^K?1"]2Y4.H2",/^
M0;R/Y3N<0+T^)2O9#A6`3\:OO_HVSA#A^:1"->&W*\&Y"MP+QOS>8O8`$>DP
MXULFY@[8%V,/[Z#VS$Z]WVL*D?\`Y"GSQ_I$P5-V^3:MQ*<)4+^6']&J*AW@
M,Y>^//B[A+-J'+.Y8WIF2[;DR(7K[BW8^G+;,/Z)'4^*3:HM)&*J-B29Q:%@
M6>CV!42$5C&.)1W*.K==?-H]0=SWNA<VFU5/VUJF(7H=0VD.E:C,I+B)G3(3
MD9#B(J_T8W1L;;UJKD;G<817N5,T:V5N*+82,B&UB05/"8)/#`1:.XN<MO'K
MRXM4]`\7K1B[(ULH49'VJ:1@L:24`]@8]Q(?`QTJF\L%-@B=SYB4"D%!0RI#
M!OL`>NJM;GVMO_:E*V[N=NJIZ>I4I"=3P4%$`%0(2XK@<9RBQFWMP['W/4N)
MVZ:9^H8`4HADI*<9`@J;3C/LRC8O/_)OV;X0<KLE%6!NZJ^!,FKQBPB!1)-R
M%6D8B"$/4-SC,R"`%#VF,(!^NN#8EM%WWI:[<I.I+M>P%CM0%I*_8$!1/=#A
MO>X?*]H7*N2=*T43ND_E%!2GVZB)1^>IPS>7_@_D7@IY`'IED<7VS-]WI3Q=
MJ55,XUVE.:[5,G1[Y8=TE$Y>K7=RHV#V"=DJ/M3]/H)O5-OWI;+WL!N2[LQ0
MH<3@)ZUZE-$>"F])[`N*-;1-9M*XVG>Z_P#MSU8M"CB`$H*0X#^@X9#B1%R/
MS]<HVN"O')=HFO3"(6/DG(0^(*PY9N-SK5BPMU9Z\R;-1$VYVJE&C'+;N%]`
M,^3_`'#5..@VUW+]U$86^V54UO"GU@REJ1Y4!79^T((EQ3%KNM6X!9]BNHIU
M`5-<4LH(XI5YE2\4B7MBN1X>*A=>%GESX^8TR0G\NE<T8+2!PS#J0^&C\RXB
M:Y8K$:Y*<1ZG;"1A&[54`_WE(P;!MJQ_62OH-Z])ZZYVO2XBBN!DK#)E]3*U
M#/-./#`B`'TIHZO:74RCH*\*0NKI`98Y/,!Q(.61*0>\&+4GE&F9%Q7<,8^9
M+'22MMRDWKE(HB!5W$8VCXJ,Z]O0Q47%A,8`'^(`']-?%7U35;[U!9-M-+*6
MJRM45$',I"4)!'<70?$187JB\IRGH;;B`\^2?9)(^@KG`;^?+/\`+\1/'K2L
M%XN>.:T_S9)L</KR48H=J\8XVK-:4EKT@S=("FLW>6%-%JQ6.40,=L]<![3;
MA]$/3#L2VNWVEI%-)^766C0M+<O*7!I0B?;B5+Q&)$%FQT#5,TU2H`#++:4C
MV"7URC?7AN\:^(N)'&S&&4)BG0<[R.RO3*_>[G?99@VD):K-;1'MYN'H=06<
MI*?3L57HQZDBY%KVU7KPJBBIS%[1$_?5[J->-W;BJ;>V\M&WJ9Y3;;0,DJT*
M(*U@>^I2A,:IA(EI`Q)Z:JI6XLH!DV#*4-"SIQ\PWR6Q]-XNSCCZN9#ID\S<
M-'$=/,$EW+`ZY.DLE`RA2DDZ_--#`!T'C-5%PB<H&*<!#0SLM\O&W:]%SLK[
ME/6H((4E1$Y?=4,E)/%)FD\1',AQ2#J1@8Q.H8VPIPDXYS4'B*@PE"Q=A^D6
M>WC7X)#LF>DKD$ZF963EI%857\U/RJ4:(N7[M19TN?83G'8`#JJJ^\[RW`AZ
MZO.5%SJGT(U*_+4$I2D9)2)R"1(">49*EO.369J)BD;XX,F\(\W<L,U<U_*7
MFJH!:'-K1LN/,:9"CK%.P=DLDTHY>DFY6-C(28CWM3QO$(-(V)BEP!KW-CF3
M,5`@&NCU$M6\[-M*BV5TSHW32<LI=>:4A"@A,@4S4I*@MQ1*U+':0".#M4)?
M0T&64G3(3(BW[A3R,^/'DA;H7C]A3.N.,AV>R1DJA"XVBJU8F[21B(.+<2LL
MV28RU5CX,K%E%-%%#)',4HD((%*([!JI-ZZ?;\V[1JOMXH:BGID+$W2M&"B<
M#-*RJ<\C(PV*8?1-:DD2XPP-)%)!)-!!--%%$A$D44B%32223*!$TTTR`4A$
MR$```H````;!J"G45:B9DXGMG_KXQIG],4Z>%'_Z6.5/_>O(W_PNKZMWO'_\
MY6S\RE_6,.;O_;T^R+C6JBPUPLOS*?Z87,?_``L+_P`4US1!Z4_XC6?^-1]L
M;Z7^L(\8$'\;K_3;9_X[Y;_Z6`U+_4-_B2]_"4_ZD;KA_63X0_+0/CBBHQ^3
M)@7++JW\:^5L!5G5SQ'C&"D*;>6Y&;F3B*I,#;V5JBW]L:-R',TJ]P0)\O<.
MS`")#MR)J&**J?5:OTX7ZTHH[GM5]WDW6J6%MF82I:>64*2V3FM'O@9]F1AS
MH'$!"VB9*5#.N$OF[X-<M8RJ8ZFIQG@+*DS'L(`,4Y)19QE3DWZC8&?R.CW$
MA?H^;C7`%!)HU7.Q=JD,5,&W5[NAGO7HOOC:CKM>TV:^U-K*N>P2I0`,]3B/
MWB3+$F2DC/5'.]2NM*)S3VB'3=M'M?#]DG8[?9[/03L]KIZ.UV]NCM]/N].V
MVWI[-!S5]_\`*SGCGGXSCDGC&&6O(6/*6^KL-=[I4JJ_O#QW#52-M,]$PJUK
MDFK3XMY%0C>5<M_G#U)F(G.@B"BG;W'IVWUUTE!7U3;K]&RZZAA(4M2$E6A,
MY)4HC`">`493CAJ:ZBI'$,5;S;:WE%*$K4$ZU`3(2#GAB0)Q7*\Z_CTX%1'%
M'*G)QC5J'@S.U?"/D:C,4PT?5FV6['(RT<R/39>FLE$(BR/IAFNLH1TV:E?-
MSD%=10R)%2C8OH7O_?2]VTNV7''ZZR/$AQ#DUEE(!/,2YBM&G`8JTR.F6(@%
M]8MC[+1MJHOZ$,T5V:(+:FI(YJB1Y"@22HD3,T@*PF3*<$Y^.S?,C7OQKTW[
M@R$K+-J=DW(U&Q[(S!UEW"F/8-Q%JQ;%L[<;JNXV$F'S]@V'J,5))L")=BI`
M`1KU"6^VV_J6]\N#:7'J9IQY*```ZJ<YRR4I(0L]I5JQG$@Z&5MPKM@LFX%2
M@V^XAHJ_W8"2`#Q"5*6D=DM.`3!>^7'_`$T>:?\`@3;?^0WU%NDG^)5E_CD?
M;$HZF_\`@%U_A%?A$+S_`!D?].NP_P#N1R;_`,/4+1#]3'^(3?\`]>U^NY$"
M]/7_`(0Y_&K_`.&U#A.;`";AQRO*4!,8>-V;M@*`B(C]MK)[`#U'0=V8L)W?
M:R2`/F%/G_ZJ8*F\!/:MR'_0O_\`#5%07P)\'.`G+["6:WW*6IU>XY(IF3(I
MG"-I+(]BJ,K'T62I\2X:+EBH6S09'4<YGB/2@Y,FH/=(8G4'2`:MKU]WOOO:
M5\HFMKU#]/;G:56K2VE:5.<P@XJ0J1"-)`!'>(K#T6V?LW<MKK7-Q,MNW!JK
M&D*<*"&R@$&25IF"J>)'"+2?%#@UP0X9VJS67C)4JQ1;/?8AA5IU=ODB<LRT
MO&-)'Y@Q8(L[%:)A)-0'X@8!1(50X^[N(>FJM;IWOO?>-,W3[FJ'ZFGIU%2`
M6TIT$@!1&A*>`QG%C-M[1VAM1Y;VWVFF7WDA*I.*5J$YCWE'C++N@.OR(LEC
M0/&+DN%2<BW=Y7OF+\;H%`P`=9NK:$+E*IB&X&$AXFGK%-MZ>\&_H.IOZ>[;
M\?U.I7B1*E9>=RG.2"V!W?O,^Z(CUTKS1=/7VDF2JAYIL8]BN8?U/KA<N2.#
MX7[\;+#C5E!".0<2T1'EG$D*V$[]8DS/6.TW)L0"@"@?&8UM;DP@&_6=LF/Z
M!J?VO?":'U'5CKJR+=5U!HEB>`DE+2?&3R)#\XF(/<-GIJ^@M,E"!\73-?&)
M,L?,M2U'_P!I4_T1"NJ1F:X^7;-_B?X=3:4P[K^"Z5'UW+:S@"G;3:5/DE7]
MUM`%`PE62<X>H<2S[JGO&?.EB_Q`(E*ML5+TBL6ZMXM*;345SRC3R(!1S1Y$
M`RF/VKBU2X!*?&!M1W>KZH7?;NU5A19HF4H?G,ZM"CK4KM_8H3CGJ)AC/F;0
M:\;?,;XZ>2K!!..AI-+%+*4,B0C9H5#'>5U8":1*)0*0B9*==4$CAZ`5$`#V
M:'?1Q9W)T?W)MMV?,;#RP3B?VK04"._4T3/OB?=54&P]4K'?&))0X&4]@`;=
M*5?0A2?9(0[GRBQ+YI7\*Y!9MSJHU&ZR+1TH4!$J*L@WCI:.`X@`](++UTY`
M$?3<0#VCKY*>J>D73V^Q[B2DJ:HJ\A0`F<=#B?I+4O;!1ZH,J2S0W%()##YG
MX$)5GWE$AVF`8_(;PA+\E>`>.<^X[;.+`AA2QL,ES#:.*+A0<:7RM_)K'.)I
M)=2B@5YRHP<N``HBDU(NH;8J9M?1WTP;SMZ=PM++J11WBA1RU3&DN8.-@GO&
MI([5$""W9*UJI0W4-D%MYM*@<QB)^V#:\0G/7%_,?BEC*$8V2);9OQ+1JU1,
MKX^6=MT)]J^JT8W@6EQCHXZA7$C5K4T8)NTG2)3)(K*G;J"51,0%DZK['N6S
MMT5"G&UFS53JG&'0"4%+AU:"J4@M!)!3GA/*/=4PMITS'E.,,GR9E''F&:/8
M<E95N,!0:'5(]>4L%ILTBA&14<S;IF4,)UEA`R[E4""5%!(JBZZ@@1,ASF`H
MCNWV^ONM8W;[:RX_6.JDE"!J43W`?6<@,3A'.`5&0Q,8*O,XVY7<?+&?&MWK
MUUQUFK&MGKT-<JS((RL.[C+C7'T*=RFNV,8R:[0K\0604`BZ"A134(0X"4.Q
M*+EM;<#9KF7&+E15"%E"QI*5(6E0F#GE,<",09&-@!;6-0(((BBQXP^-O!Q[
MR6S%PN\DU(D*WEV(M7TMC.Q2M^M&/X8MHK3AY$S]`D5(J4BH_P"-LZ?PTC".
MG`@1XF)DTSB91`I[M]2]Q[S1MBBWETZ?#EG+.IY`;2M6E<BEP3U&2#-*TCW3
MB<C)VJ''BV'J<^66,6Y..7B#X(<4<N5S.N%,93];R+4V<XTA9E_D:[S[1LVL
M4.[@Y8%(R:FWD:X[T8]4*4QTQ$@CU%V$`'54]Q=5]\;IM2[+>JD.V]Q25*0&
MT).I!FF12)C'@##8NJ>=!0HX&&<`8!#</4/T]=#77W2/?&B44R>)5JK5/_)2
MY,.;9/Q%:;2]KY!046YGI!K$MGTS(04`[CXMNY?*(('?/V[-4R"?5U+=&Q-Q
M$`&X>ZJ>HJO3G;?AD*<"6Z8G3YB`E:@HD#$!.$SD)XPZ.))MZ98Y1<0^N*7_
M`.;JO_Z@B?\`M>JB?#U/!M<O`_Z(;-*NPPN[S$+)2/B\YAN&"B;YNMB8'*"[
M-0CE%9N6RUY8SA)5$3IJ(E1*)A,`B7I`1WVU/>E(5_>19T$'5\:C#C/'#QC=
M3?UA/C`-?C@7VCMO'FXKSJX5AK/0F=<FGEX5U.QK65C4Y1.OO(U9XP<.4G2"
M$@U'K14,0"*@!ND1$I@";^H:BK!U$6_RG.0Y1L%*M)DH!,C(B8,B"#V$8QOK
MTJ-02`92A_K6VU5\X2:,;+7WKM<W0@U:34:X<+&`HF$J2"3DZBA@*41V`!'8
M-`I3+Z`5+0H)'$@C[(X=)&8,8]9+SC!M/L,86ZU4AO9KI#2+R+H5DF(1*5M<
M"V4282RK&NRBY5YR.15=D2<`FDJ0O<`#!ZZW4]'<5L*N=(V_\*TL`NH2K2A1
MQ2"L"25<1.1[(RE*CYD`R_!%4?\`()X#<'L*8/B^0.*Z]4,)YSE\AP4(A1:8
MY:0T+E.*F57:EB?$H+=0&D>_K2!"O1D8]%LD0I127`YE4A+:3H!OO>MYORMO
M71QVMLJ:=1*W9DM%/N#FG$A4Y%*B2?NG"'*B>=4KEJQ:,%A]]>1?_P!;S[N_
M.K+]WO\`+S\C^LOBW/U7]`_<;Z$^K/C?^N_,/M?_`#?B^KN]'^T]?5[VHI\C
MV]_F(^4:&OE'S*>B8Y?,Y7-T]FGG^73^A&K2W\?I^YJAB/DE\76*?)57L<QN
M1<CY*QU,8H=V%]39.DN(9U%%=6=**2DEYJMS<<Z0DG!"0J`(+)+M5D2]90/L
M<=07IUU-NO3BJJ'K=3TU0U5)2'`Z#JDDDI"5I/E`))(*53\8%^^^GENWY3L-
M5M0^PY3DZ"V1I\TM6I!&,](E)0E"JJ?^+[AKZBBWN8N76<LI56)=%.C5&</#
MU11=F0Q1,P&>?RMQ<QR#D@="@LT6ZG2/N'*.P@4*KU-WHT[B+3::"EK'#^\F
MI<N_3I;!/'$G',&!S3>GFT<Y"KE<JNHI4'W`D(F.R>I8`_1GWQ9*Q/B?'N#<
M<T_$N**M&4K'="A6\!5:Q$)F391D<VZC[=:IU7#IVZ<*'6<.%CJ+N7"AU53G
M4.8PUTN=SN%ZN#MUNKJGK@^LJ6M69)^H``2`$@!(```0>+9;*&ST+=MMK:6:
M)E,D(3D!B3WDDDDDXDDDF9C`.5V`V?*3CCF/CP_LKNG,LO4B5I3FTL8U&8=P
M:4H"8&D&\8X<LT'JB/;]$S*I@._M#3CM:_N;6W%1[A::#SE(^EP()TA4N!(!
M(]@,<FX[*C<5CJK(XLMMU+105`3(!EC*8G](\8T#XV^!D1XZ^/TA@2$R5*Y4
M9O\`(EDR"-EEZZRK#I):Q,(-@>++',9*51,BU"$`P*BKU&%00Z0V#=^ZB[\J
M.H=^3?:FF12N)82UH2HK!"2HSF0#/S92ACV'LMG8MG5:&'U/H4\7-12$R)2E
M,I`JP\L\\R8/"7B8V?BI*#F6+63AYF/>Q,M&/42.&4C&2+91F_8NT%`$B[5V
MU6.FH0P"!B&$!]NH*VXZRZE]A10\A04E0S!29@^PQ,G6FWVE,/`*:6DA0.1!
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M(N3RU4[R'`DM`:M"DJTD\PR!E(X'`F&A^3GQPQODKQAC[%<[F6PX@A*->'5Z
M66K]4C+2K/R)Z_(5^/0=)2<K%IM$XU"5<*%,43B<RFP@&V^AATVZB.].;E47
M2GHVZI]]CE#6I2-`)F2"D&<Y"?@((F_MAL[\HV*&IJ5T[+#I<\J=6HR`$_,G
M+'CQ@X*7B6KU##%6P8*!)BF5G&,)BD[9XW33)+5J(JK:I*)/&Z?4B4)&-0$%
M2%W+[XAJ%UETJJN[NWLDIKG:A3TQF%J65S!SP4<(EE):Z:EM#=EEKHVZ9+,C
M]Y`1H,QEB,Q"GO'+X3L2>.W.-YSC7<KV;*<Q8ZA(TFJ1EFJD/"IT.%EIYI+O
MSL9!A)/EY.0<,HULR,L<B/\`)*H.W\P0`J]1.M-XZB61BRU5*U2LMNI6LMJ4
M>:4I*1J20`,Y\<0.R!OL;I):MCW=V[TSZWWUM*0D*0!HU$$D'49F0ED,SW2V
MWY-_%I4/)2SPO\[RS/X>FL+3-HE(B>KM5BK0YE4+.C!@I'NDI.2C`;),7U?0
M<)F(<VYMP$/7?3-TWZGUO3HUJ6:9NK8K6TH6A:U(`*=4E#2#/!1$LL8<]_\`
M3FBWX*4U#ZZ9ZE*]*DI"CYM,\U)D1I&,';E;#D?EO#<IBBTR1WJTA`L&2=E4
M;$(Z1L<4@@=A92MBF.5);YFV!91,IO4ASI]6P[Z`_4#:M#OS;U;8*L<IJJ!*
M",>4Y.;:D_F'/M3,1++K96+K95VFJ.H%L`*.86D#2OQU`$_1"TN.&?7''N2F
MN)G*:-285UHH_B8.:FFH2%>3AY@5TUXB63<I+-I*BSR3@YVSD2G12*L=%8`)
M_=U@Z5]3;ATKNZNF74752(IGC\+4F>E`)FGS_P"Z4?.VXD^3%)D!@.MK[C?V
MO4G:VXP6FVU'E.GW0G/%7XA/NJX9'*`/Y&_CK4BV7H<W\`^0[OCK)2KI::CJ
MP5Q,RE)B5GB@KG/CV\4V79VRL0ZBH[D:":102+L5(4TRE3#ZK;1]2"JFSMT.
M[J1B\VI38`>06U%U(`"=04%-N9>_,3PPXP;J>Y(=:"CI<:(F%`@@CN,Y'MC4
M<5^/%R]S9888_-;R!SM\I<,L10(J&E\C9*GSH);?RHI]E&1;P-?<*E#I!Q\$
M\,GN(]!O9I[7Z@-J62G6O9FW6::X*PU*2TVD#C,,@*5CC+4)Y3$;E5S+8DTB
M1[>$.%K>1^'?C.QG4.->`*U\UC(*6*O8(>O2Z4M+)NI%1`;+<+O:'`G1E[Q*
M]H#F;[E.<Y2I]+9$B90H)UD]3MFI=Q?%7A[YK?WG0EQ%.I.BG;'W9XI24))T
MM3*C(E1!F2.=R;^M=FJ4,+_;UBE>9*"/(.,SE/L3F8UGS$\9O"3RPQ#/+D%:
M%:5EY.+:QZ67<=$CE)UPU:I@#"#RA2Y($T9T8C^PB+CX210(`$2=`B!2ZL%T
M;]1#M!:TU.TZMBY;<<.LTZU?NU_>&D>=E<_?200HS,CG$KLVX*.X4XJ+>XEV
MG($P#B">"AFD]H(A9BGX^G.Y:-''2GDZL:F']O@_ITZ^9A0^6?V/A_I#[B_3
MX%[`[=KXCM?P^S1Z'7?88/QPVPQ\XS*PFG`GVZ^5JG/C*?&'OXUC/EX^R+'>
M%VD)QAQ!A;!&5\_M,@W6MUJ,I+&\WU>%K-JOAHE%1&/=.HI)ZL4JZ$8FDV[I
ME%#KBD4RBAUE#":I^\=Z[8.XW*BJ<HK6[7U!4U3\U."E8E*=4CI)F02`,=(E
M@(8JRYV^E?2BJ=::6X?*%*`GX3/=X3PA:G/SP3<=^=&77&>V61;G@[)5A:1R
M%W?U&(@[)7+LM%-46,7//8.5.R.PL:<>@D@H[:NB%<II)BHF90!4,<-A=;K[
MLJSBR&GIZZU))+0<)2I&LS("TSFDDS`(P))!EA#JQ6K:0$R"D\,8!(WXLV.0
M`1-S7RF4-O4PXQK```?TB-J`-3O_`#/7*8*[+1D`2Q>6</`IC<;CA[B9>,6&
ML3<6:-0^(U)X?6UP.5,>5S#3#"M@=6!@FP/=JTA7OIV07D6+-RN1BM*,C&,/
M96$R)Q`2'`Q0$*_W7<U9<-U/;MHP*2N<JS4)#9P;45:@$F0F`<ICV1P*62X5
MC`SG"!+1^+7@UY8I=_1^5^7J?6GCI56*KLA3:I9WL2R,H8[>/5L19"`6EB,R
M&Z"**MP5$H;F$QA$PGBD]3-[;I4,UUKI'WP!J7S%H"CQ5I`4$SS(!E..X7%<
ML4@F-V\2/QZ:1Q0Y(8EY%QO*O(5Y?XIL2]A;5*6H$!%1TVHO#2D.+5U(-;$[
M<-4RDDQ4ZBIG'J(`;>NF+>'7NMW;MRIVX[:Z5AJI2D%Q*U*6G2M*YB:1G*1$
M\H\.UQ<;+>@"?&"R\COA[Q+Y&+I2LG6G+^5<6Y`H56/3Z^^JQH.8K:,.>6=S
M)U35R69HN4)55\\-W'+9^W,H0B93`/0`ZB_3OJS=>GM(];Z:DIJJWON!Q27=
M05K`"0=0.4A[I3GC.-=/5*IP4@`@P#.+/QFN/D1<HJSY]Y'9FY`Q40LDH6GO
M&S&F1<H@@J"I(N8F$I*R60\.OT`"R#)TQ,<NY0.4!U-KEZDMQ/T:Z6R6^CH'
MUDS<&IPC"7E"DI3,'$%04.T&-QN"PG2A*4Q8M^W%#^WWVH^DH#[:_27T']#?
M+&WTQ]&?*?D7TQ\HZ/A/DWR?_9NQT]':]W5?/C:WX_YIS5?,>;S.9/S<S5JU
MS[=7F\8X=1U:YG5&:ZYH\Q-*%$TH432SA1-8``RA1-9A1-*%$TH432A1-*%$
MUB%$UF%'`AO^^L2A1IC,F`,6YVA21&0ZXE(JM2*%BIUF?X"Q0IE!W.,9+(E%
M9-,X^ID5`4;G'U,01VU"MZ=/MJ[]HA1[DI@ZI(.AU/E=;/Y"QPXZ532>*89;
MUM^UW^GY-Q;U$>ZL8+3^:>SNQ!X@P!Y/'SE.@N5C8,Y.6FI1QSF.G$R))5B5
M,##OTJK0$HFP<&]FYO@BB;]0T`O\O&[-OO*5L3=%52,$X(7S$@#L/+44J\>6
M(@G]WMTH%'Y'<WFFB9A*M0'\TX^,A'O7X4<H[BG\MR-R\G7<$J/0[9Q1[*[%
MP@/NG(9!63AFQA,7</?`Y1_4-;5]$>J=XE3[DW>^JWD24EM3RM0XC2HH3+QG
M"_L7NNM_97*[K53G,)*YD=DII^LP0>)^"/'[&48^0>5LN0Y>78KQ\G.7E-M)
M*&;.BF(Z3C(Y-%)A#@L`_P!XD47("'][HB[2Z"]/MKTJVWZ87&M>24N.U(2L
MD'/0D#2B?XPFO\N)#:-B;?MC"FUM_$N.)DI3F),\Y#[OCBKOC2-K\;<*PG%K
M+@O+%OQ/(F4,HDP[KN29M]S=0(M)1A(Q$VBU(;^R191SL'Z^FH-=?3314M<;
MKL*[5EHJR20G4I:1/@E84EP#QU'OADJNFU.W4?%6*J>I71D,2!W:@4JD,L=7
M>3'7_P"4CFDN7X!YS%DBQ8AVSF0>6P[SM"`%'U[[98QA+^@N/Z]<G]T'6U:/
MAWMX+^&[EU`5+CCX=\:O[)[U4.6J\GE]Q7/[(^R.\8M%D&$HZR)E3(%QN4DD
M7IL:9VK1)DX`X'%;X23^=NY/?;;9=SMT^P"CL(;6/2[8:IIQ[<5VN%9>W!^]
M!"0E7XQ2O65]Y*DS[HV(Z8T#J%+N%54.UBA^\P`GVD*"Y_2(\ZOPIY"8W>E;
MT+E+.!64QZ48B2^HF)4DBB`$*5HC*RT>`E(&WN$3*'Z!KW;NB74/;E1RMO[J
MJ/E2?=;<YR=([`A*EH]H`[HS2[)W!;7-%ONBQ2C))U#Z@2![)06U)Q-?8T4%
M;SDE[:%$A*)DP%\HD8P>T=WB_0&X_P#-Z+MCVE?J?0N^W-=4M/":],^WS'[(
MEU#:;@T0:VI4[+Q^V"$3("9")EWZ2%*4-_4=@#8-Q_?TT1DI"4A(R`B0##"/
8/62D'.,Q-("6`A1-9A1-8EPA1-9A1__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
